Sucampo Pharmaceuticals 10-Q 8 Nov 13 2013 Q3 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
	Sep. 30, 2013	Oct. 25, 2013
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'Sucampo Pharmaceuticals, Inc.	'
Document Type	'10-Q	'
Current Fiscal Year End Date	'--12-31	'
Entity Common Stock, Shares Outstanding	'	42,470,364
Amendment Flag	'false	'
Entity Central Index Key	'0001365216	'
Entity Current Reporting Status	'Yes	'
Entity Voluntary Filers	'No	'
Entity Filer Category	'Accelerated Filer	'
Entity Well-known Seasoned Issuer	'Yes	'
Document Period End Date	30-Sep-13	'
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Unaudited) (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$39,911	$52,022
Investments, current	15,263	6,035
Product royalties receivable	13,595	14,175
Unbilled accounts receivable	'	732
Accounts receivable, net	2,694	1,360
Deferred tax assets, current	1,273	874
Deferred charge, current	673	673
Income taxes receivable	2,013	'
Restricted cash, current	26,141	15,113
Inventory	261	'
Prepaid expenses and other current assets	3,835	1,930
Total current assets	105,659	92,914
Investments, non-current	7,259	14,408
Property and equipment, net	1,278	1,540
Intangible assets, net	6,686	7,415
Deferred tax assets, non-current	1,162	1,654
Deferred charge, non-current	4,709	5,213
Restricted cash, non-current	2,430	3,832
Other assets	537	820
Total assets	129,720	127,796
Current liabilities:	'	'
Accounts payable	2,934	5,496
Accrued expenses	6,211	10,595
Deferred revenue, current	1,148	3,700
Income tax payable	'	148
Notes payable, current	28,114	19,129
Other current liabilities	1,286	1,003
Total current liabilities	39,693	40,071
Notes payable, non-current	29,812	33,722
Deferred revenue, non-current	6,490	7,093
Deferred tax liability, non-current	2,632	2,627
Other liabilities	1,296	1,253
Total liabilities	79,923	84,766
Preferred stock, $0.01 par value; 5,000,000 shares authorized at September 30, 2013 and December 31, 2012; no shares issued and outstanding at September 30, 2013 and December 31, 2012	0	0
Class A common stock, $0.01 par value; 270,000,000 shares authorized at September 30, 2013 and December 31, 2012; 42,389,346 and 41,964,905 shares issued and outstanding at September 30, 2013 and December 31, 2012, respectively	423	420
Additional paid-in capital	65,758	62,521
Accumulated other comprehensive income	15,763	16,166
Treasury stock, at cost; 524,792 and 457,030 shares	-2,313	-1,977
Accumulated deficit	-29,834	-34,100
Total stockholders' equity	49,797	43,030
Total liabilities and stockholders' equity	$129,720	$127,796

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Preferred stock, par value (in Dollars per share)	$0.01	$0.01
Preferred stock,shares authorized (in Shares)	5,000,000	5,000,000
Preferred stock, shares issued (in Shares)	0	0
Preferred stock, shares outstanding (in Shares)	0	0
Common stock, par value (in Dollars per share)	$0.01	$0.01
Common stock, shares authorized (in Shares)	270,000,000	270,000,000
Common stock, shares issued (in Shares)	42,389,346	41,964,905
Common stock, shares outstanding (in Shares)	42,389,346	41,964,905
Treasury stock, shares (in Shares)	524,792	457,030

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) (USD $)	3 Months Ended		9 Months Ended
Share data in Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Revenues:	'	'	'	'
Research and development revenue	$2,027,000	$737,000	$16,288,000	$6,418,000
Product royalty revenue	13,595,000	13,890,000	37,271,000	36,521,000
Product sales revenue	5,378,000	'	10,994,000	'
Co-promotion revenue	'	730,000	61,000	3,253,000
Contract and collaboration revenue	163,000	139,000	490,000	433,000
Total revenues	21,163,000	15,496,000	65,104,000	46,625,000
Cost of goods sold	6,267,000	'	9,457,000	'
Gross profit	14,896,000	15,496,000	55,647,000	46,625,000
Operating expenses:	'	'	'	'
Research and development	4,474,000	5,615,000	14,528,000	14,202,000
General and administrative	5,440,000	7,256,000	18,635,000	22,598,000
Selling and marketing	6,026,000	4,278,000	15,967,000	14,474,000
Total operating expenses	15,940,000	17,149,000	49,130,000	51,274,000
Income (loss) from operations	-1,044,000	-1,653,000	6,517,000	-4,649,000
Non-operating income (expense):	'	'	'	'
Interest income	20,000	68,000	63,000	118,000
Interest expense	-461,000	-596,000	-1,449,000	-1,780,000
Other income (expense), net	-49,000	8,000	1,776,000	727,000
Total non-operating income (expense), net	-490,000	-520,000	390,000	-935,000
Income (loss) before income taxes	-1,534,000	-2,173,000	6,907,000	-5,584,000
Income tax benefit (provision)	2,825,000	-3,776,000	-2,641,000	-3,112,000
Net income (loss)	1,291,000	-5,949,000	4,266,000	-8,696,000
Net income (loss) per share:	'	'	'	'
Basic net income (loss) per share (in Dollars per share)	$0.03	($0.14)	$0.10	($0.21)
Diluted net income (loss) per share (in Dollars per share)	$0.03	($0.14)	$0.10	($0.21)
Weighted average common shares outstanding - basic (in Shares)	41,863	41,678	41,644	41,697
Weighted average common shares outstanding - diluted (in Shares)	42,787	41,678	42,662	41,697
Net income (loss)	1,291,000	-5,949,000	4,266,000	-8,696,000
Other comprehensive income (loss):	'	'	'	'
Unrealized gain (loss) on investments, net of tax effect	18,000	28,000	-16,000	23,000
Foreign currency translation	-253,000	-175,000	-387,000	-1,767,000
Comprehensive income (loss)	$1,056,000	($6,096,000)	$3,863,000	($10,440,000)

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) (USD $)	Common Class A [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Treasury Stock [Member]	Retained Earnings [Member]	Total
Balance at December 31, 2012 at Dec. 31, 2012	$420,000	$62,521,000	$16,166,000	($1,977,000)	($34,100,000)	$43,030,000
Balance at December 31, 2012 (in Shares) at Dec. 31, 2012	41,964,905	'	'	457,030	'	'
Stock issued upon exercise of stock options	3,000	1,540,000	'	'	'	1,543,000
Stock issued upon exercise of stock options (in Shares)	421,595	'	'	'	'	'
Employee stock option expense	'	1,376,000	'	'	'	1,376,000
Stock issued under employee stock purchase plan	'	17,000	'	'	'	17,000
Stock issued under employee stock purchase plan (in Shares)	2,846	'	'	'	'	'
Foreign currency translation	'	'	-387,000	'	'	-387,000
Unrealized loss on investments, net of tax effect	'	'	-16,000	'	'	-16,000
Windfall tax benefit from stock-based compensation	'	304,000	'	'	'	304,000
Treasury stock, at cost	'	'	'	-336,000	'	-336,000
Treasury stock, at cost (in Shares)	'	'	'	67,762	'	'
Net income	'	'	'	'	4,266,000	4,266,000
Balance at September 30, 2013 at Sep. 30, 2013	$423,000	$65,758,000	$15,763,000	($2,313,000)	($29,834,000)	$49,797,000
Balance at September 30, 2013 (in Shares) at Sep. 30, 2013	42,389,346	'	'	524,792	'	'

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Cash flows from operating activities:	'	'
Net income (loss)	$4,266	($8,696)
Depreciation and amortization	1,117	1,105
Deferred tax provision	-201	-19,511
Deferred charge	504	23,754
Stock-based compensation	1,376	1,683
Amortization of premiums on investments	81	49
Notes payable paid-in-kind interest	'	1,656
Unrealized currency translations gains	-1,800	'
Changes in operating assets and liabilities:	'	'
Accounts receivable	-1,334	3,381
Unbilled accounts receivable	732	1,464
Product royalties receivable	581	-2,551
Inventory	-218	87
Prepaid and income taxes receivable and payable, net	-2,159	-467
Accounts payable	-2,428	-3,513
Accrued expenses	-4,231	-1,853
Deferred revenue	-3,039	-45
Accrued interest payable	395	'
Other assets and liabilities, net	-1,820	-1,711
Net cash used in operating activities	-8,178	-5,168
Cash flows from investing activities:	'	'
Purchases of investments	-7,910	-5,929
Proceeds from the sales of investments	'	750
Maturities of investments	5,760	24,345
Purchases of property and equipment	-153	-306
Purchases of intangible assets	'	-3,000
Purchase of other investing activities	'	-432
Restricted cash	-10,031	-1,364
Net cash provided by (used in) investing activities	-12,334	14,064
Cash flows from financing activities:	'	'
Proceeds from notes payable	10,600	'
Repayment of notes payable	-3,725	'
Proceeds from exercise of stock options	1,543	67
Purchase of treasury stock	-336	-556
Proceeds from employee stock purchase plan	17	15
Windfall tax benefit from stock-based compensation	304	'
Net cash provided by (used in) financing activities	8,403	-474
Effect of exchange rates on cash and cash equivalents	-2	-1,838
Net increase (decrease) in cash and cash equivalents	-12,111	6,584
Cash and cash equivalents at beginning of period	52,022	50,662
Cash and cash equivalents at end of period	39,911	57,246
Supplemental disclosure of non-cash investing and financing activities:	'	'
Purchase of other investing activities included in accounts payable	'	$2

Note_1_Business_Organization_a

Note 1 - Business Organization and Basis of Presentation	9 Months Ended
	Sep. 30, 2013
Disclosure Text Block [Abstract]	'
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	'
	1.      Business Organization and Basis of Presentation
	Description of the Business
	Sucampo Pharmaceuticals, Inc., or the Company, is a global biopharmaceutical company focused on innovative research, discovery, development and commercialization of proprietary drugs based on ion channel activators known as prostones. The therapeutic potential of prostones was first discovered by the Company’s co-founder, Dr. Ryuji Ueno, and under his leadership the Company has pioneered the field of prostones. Prostones are naturally occurring fatty acid metabolites. Originally thought to be biologically inert, prostones have emerged as a promising compound class with unique physiological activities which can be targeted for the treatment of unmet or underserved medical needs.
	Prostones act locally to restore normal function in cells and tissues. They are quickly metabolized to an inactive form, and therefore, their pharmacologic activity can be targeted to specific organs and tissues. Prostones possess a unique mechanism of action as highly potent and selective ion channel activators. Ion channels are integral parts of cell membranes that regulate the flow of specific ions into and out of cells. This regulation is key to the functioning of cells, such as metabolic processes and cell survival. As such, prostones are physiological mediators of the restoration of cellular homeostasis and tissue regeneration. There is also evidence that prostones have anti-inflammatory properties and can prevent cell death.
	The Company’s prostone-based compounds target the ClC-2 and big potassium, or BK, ion channels. Because these ion channels play an important role in physiology, targeted dosing of prostones may have broad applicability in many disease states in different organ systems. The Company has developed synthetic analogs of the naturally occurring prostones, which have been optimized to be more potent, selective, and stable, thus enabling their use as drugs. Prostones are very selective for their molecular targets, and the approved prostone-based compounds are well-tolerated and generally safe.
	The Company is focused on developing prostones to treat gastrointestinal, ophthalmic, neurologic, and oncology-based inflammatory disorders, and is also considering other potential therapeutic applications of the Company’s drug technologies.
	The Company currently generates revenue mainly from product royalties, development milestone payments, clinical development activities and product sales. The Company expects to continue to incur significant expenses for the next several years as the Company continues its research and development activities, seeks regulatory approvals and additional indications for AMITIZA® (lubiprostone), RESCULA® (unoprostone isopropyl) and other compounds, and commercializes the Company’s approved products (as discussed below) on a global basis.
	To date, two prostone products, AMITIZA and RESCULA, have received marketing approvals. A third prostone, cobiprostone, completed phase 1a clinical development for the target indication of prevention and/or treatment of oral mucositis, or OM, in the second quarter of 2013, and the Company has initiated the next phase of clinical development in the fourth quarter of 2013. Additionally, two ion channel activators, in both the intravenous, or IV, and oral, or PO, forms, are in clinical development for the treatment of lumbar spinal stenosis, or LSS. The Company has completed the treatment phase 2a, double-blind, placebo-controlled study of the IV version of the Company’s ion channel activator for LSS, and is currently in the data analysis phase. The PO ion channel activator completed phase 1a clinical development in June 2013 and is expected to begin the next phase of clinical development in the first quarter of 2014, pending results of the IV ion channel activator phase 2 results. Additionally, this compound may be investigated for other indications.
	In October 2013, the Company announced the initiation of a pivotal trial of a liquid formulation of lubiprostone 24mcg twice daily in adults. The Company continues to prepare for initiation of the pivotal phase 3 program for AMITIZA in pediatric functional constipation. The pediatric functional constipation phase 3 program is the first of a series of global, multicenter phase 3 studies to evaluate the efficacy, safety, and pharmacokinetics of lubiprostone in patients aged ≥ 6 months through 17 years of age with pediatric functional constipation. The program will consist of two randomized, placebo-controlled, double-blinded studies and two long-term safety extension studies. One of the pediatric trials will also use the liquid formulation.
	AMITIZA is currently being marketed in the United States for three gastrointestinal indications under the October 2004 collaboration and license agreement, or the Takeda Agreement, with Takeda Pharmaceutical Company Limited, or Takeda. These indications are chronic idiopathic constipation, or CIC, in adults; irritable bowel syndrome with constipation, or IBS-C, in adult women; and opioid-induced constipation, or OIC, in adult patients with chronic, non-cancer pain. AMITIZA for OIC received approval from the United States Food and Drug Administration, or FDA, in April 2013. AMITIZA at dosage strength of 24 micrograms twice daily is the first and only oral medication for the treatment of OIC in adult patients with chronic, non-cancer pain. Takeda also holds marketing rights to AMITIZA in Canada. Takeda and the Company are currently exploring the commercialization of AMITIZA in Canada. The Company is primarily responsible for development activities under the Takeda Agreement, while Takeda is responsible for the commercialization of AMITIZA in the United States and Canada. The Company announced in November 2013 that it is exercising its co-promotion option and will begin co-promoting AMITIZA in the first quarter of 2014 for OIC in adults with chronic, non-cancer pain.
	In Japan, AMITIZA is currently marketed under a license, commercialization and supply agreement, or the Abbott Agreement, with Abbott Japan Co. Ltd., or Abbott, for the gastrointestinal indication of chronic constipation, or CC, excluding constipation caused by organic diseases. Abbott initiated commercial sales of AMITIZA in Japan for the treatment of CC in November 2012.
	In the United Kingdom, AMITIZA was approved for CIC in July 2012. The Company will make AMITIZA available in the United Kingdom in the fourth quarter and is currently working to achieve National Institute for Health and Care Excellence endorsement for CIC and OIC. In Switzerland, the Company is actively marketing AMITIZA.
	In the first quarter of 2013, the Company commenced the approval process for CIC in other European Union countries for AMITIZA via the Mutual Recognition Procedure, or MRP, and filed for the OIC indication in the United Kingdom and Switzerland. The Company anticipates a decision in both countries in the first half of 2014. Upon the OIC approval in the United Kingdom, the Company will seek approval for AMITIZA in other European Union countries following the MRP.
	The Company holds license agreements for RESCULA in the United States and Canada and the rest of the world, with the exception of Japan, Korea, Taiwan and the People’s Republic of China. The Company is commercializing RESCULA (unoprostone isopropyl ophthalmic solution) 0.15% for the lowering of intraocular pressure, or IOP, in patients with open-angle glaucoma or ocular hypertension in the United States. According to the United States approved product labeling, RESCULA may be used as a first-line agent or concomitantly with other topical ophthalmic drug products to lower intraocular pressure. RESCULA is a BK channel activator and has a different mechanism of action than other IOP lowering agents on the market.
	The Company recently announced that its development partner, R-Tech Ueno Ltd., or R-Tech, completed patient enrollment of a phase 3 clinical trial for unoprostone isopropyl for retinitis pigmentosa, or RP, in Japan. A substantial portion of the development costs for the program are being funded by the Japan Science and Technology Agency. The Company has rights to the clinical data for potential filing in Europe and the United States where unoprostone isopropyl has orphan drug designation, and will decide on the Company’s path forward assuming the Japanese trial is successful.
	Basis of Presentation
	The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States, or GAAP, and the rules and regulations of the Securities and Exchange Commission, or SEC, for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the Company’s Consolidated Financial Statements as of and for the year ended December 31, 2012 included in the Company’s Annual Report on Form 10-K, which was filed with the SEC on March 18, 2013. The financial information as of September 30, 2013 and for the three and nine months ended September 30, 2013 and 2012 is unaudited. In the opinion of the Company’s management, all adjustments, consisting only of normal recurring adjustments or accruals, considered necessary for a fair statement of the results of these interim periods have been included. The results of the Company’s operations for any interim period are not necessarily indicative of the results that may be expected for any other interim period or for a full fiscal year.
	The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries. All significant inter-company balances and transactions have been eliminated.
	The preparation of financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Note_2_Summary_of_Significant_

Note 2 - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	2.      Summary of Significant Accounting Policies
	Cash and Cash Equivalents
	For the purpose of the Condensed Consolidated Balance Sheets and Statements of Cash Flows, cash equivalents include all highly liquid investments with a maturity at the time of purchase of 90 days or less.
	Restricted Cash
	Restricted cash primarily represents collateral pledged to support a loan agreement with The Bank of Tokyo-Mitsubishi UFJ, Ltd. (the Tokyo-Mitsubishi Bank); a loan agreement with the Mizuho Bank, Ltd. (the Mizuho Bank); a loan agreement between Numab AG (Numab) and Zurcher Kantonalbank, which we serve as guarantor; and operating leases with certain financial institutions. Restricted cash totaled approximately $28.5 million and $18.9 million at September 30, 2013 and December 31, 2012, respectively.
	Current and Non-current Investments
	Current and non-current investments consist primarily of United States government agency securities, certificates of deposit, and variable rate demand notes, and are classified as current or non-current based on their maturity dates. The Company classifies all investments as available for-sale-securities and reports unrealized gains or losses, net of related tax effects, in other comprehensive income.
	Fair Value of Financial Instruments
	The carrying amounts of the Company’s financial instruments approximate their fair values based on their short maturities, independent valuations or internal assessments. The Company’s financial instruments include cash and cash equivalents, restricted cash, current and non-current investments, receivables, accounts payable and accrued expenses. The Company’s debt is subject to the fair value disclosure requirements as discussed in Note 4 below, and is classified as a Level 2 security.
	Accounts Receivable and Unbilled Accounts Receivable
	Accounts receivable primarily represent amounts due under the Takeda Agreement and the Abbott Agreement. Unbilled accounts receivable consist of research and development expenses that are reimbursable by Takeda, but as of the balance sheet date have not been billed to Takeda. The Company recorded an allowance for doubtful accounts of approximately $426,000 and $280,000 at September 30, 2013 and December 31, 2012, respectively, related to certain disputed Takeda invoices.
	Product Royalties Receivable
	Product royalties receivable represent amounts due from Takeda for the Company’s royalties on net sales of AMITIZA, which are based on reports of net sales obtained directly from Takeda.
	Inventory
	Inventory is stated at cost or market, whichever is lower. Cost is determined on a first-in, first-out basis. Inventory is reviewed periodically for potential excess, dated or obsolete status. The Company’s management evaluates the carrying value of inventory on a regular basis, taking into account such factors as historical and anticipated future sales compared to quantities on hand, the prices the Company expects to obtain for products in their respective markets compared to historical costs, and the remaining shelf life of goods on hand. During the third quarter of 2013, the Company recorded a $4.5 million non-cash write-off of its RESCULA inventory to reflect anticipated excess quantities of dated product consisting of $3.0 million of product for sale and $1.5 million of sample inventory, compared to nil during the third quarter of 2012. The anticipated excess inventory was largely a result of the necessity to pre-order product in advance of FDA approval due to a planned change in manufacturing facility, and lower than anticipated sales within the useful life of the dated product.  In addition to initial sales falling below their forecast, the Company has recently decided to eliminate its in-house sales force and deploy a contract sales force to detail only current RESCULA prescribers at a much reduced level, which will further impact sales of RESCULA going forward.
	Revenue Recognition
	The Company’s revenues are derived primarily from product royalties, development milestone payments, clinical development activities and product sales.
	Research and Development Revenue
	The Company evaluated the multiple deliverables within the collaboration and license agreements in accordance with the guidance of multiple deliverables to determine whether the delivered elements that are the obligation of the Company have value to other parties to the agreement on a stand-alone basis and whether objective reliable evidence of fair value of the undelivered items exists. Deliverables that meet these criteria are considered a separate unit of accounting. Deliverables that do not meet these criteria are combined and accounted for as a single unit of accounting. The appropriate recognition of revenue is then applied to each separate unit of accounting. The Company’s deliverables under the Takeda Agreement and the Abbott Agreement, including the related rights and obligations, contractual cash flows and performance periods, are more fully described in Note 10 below.
	Product Royalty Revenue
	Royalty revenues are based on net sales of licensed products and are recorded on an accrual basis when earned in accordance with contractual terms if third-party results are reliably measurable, collectability is reasonably assured and all other revenue recognition criteria are met.
	Product Sales Revenue
	AMITIZA product sales consist of AMITIZA sales to Abbott in Japan and by the Company in Switzerland. Revenue from AMITIZA product sales is recognized when persuasive evidence of an arrangement exists, delivery has occurred, title to product and associated risk of loss have passed to the customer, the price is fixed or determinable, and collection from the customer is reasonably assured. The Company did not record sales deductions and returns for sales of AMITIZA due to the absence of discounts and rebates and the lack of right of return.
	RESCULA product sales consist of RESCULA sales in the United States. The Company recognizes revenue from RESCULA product sales less deductions for estimated sales discounts and sales returns. Revenue from product sales of RESCULA is recognized when persuasive evidence of an arrangement exists, title passes, the price is fixed or determinable, and collectability is reasonably assured. The Company accounts for rebates to certain governmental agencies as a reduction of product sales. The Company allows customers to return product within a specified time period prior to and subsequent to the product’s labeled expiration date. As a result, the Company estimates an accrual for product returns, which is recorded as a reduction of product sales. Given the Company’s limited history of selling RESCULA and the return period, the Company cannot reasonably estimate product returns from the wholesale distribution channel. Therefore, the Company is deferring the recognition of revenue until there is confirmation of pull-through sales to pharmacies or other end user customers. The Company will continue to defer recognition until the point at which the Company has obtained sufficient sales history to reasonably estimate returns from the wholesalers. The Company’s three largest wholesale customers accounted for 98.2% and 95.5% of its RESCULA product sales for the three and nine months ended September 30, 2013, respectively.
	Co-promotion Revenue
	Co-promotion revenue relates to a limited reimbursement of co-promotion costs based on details to healthcare prescribers.
	Contract and Collaboration Revenue
	Contract revenue relates to development and consulting activities and is accounted for under the time-based model.
	The Company considers its participation in joint committees under its collaboration and license agreements as separate deliverables under the contracts and recognizes the fair value of such participation as collaboration revenue over the period of the participation per the terms of the contracts.
	The Company has determined that it is acting as a principal under both the Takeda Agreement and the Abbott Agreement and, as such, records revenue on a gross basis in the Condensed Consolidated Statements of Comprehensive Income (Loss).
	Cost of Goods Sold
	Cost of goods sold relates to purchase and distribution costs of the products sold by the Company, including inventory write-offs for excess and obsolete inventory and amortization of marketing licenses.
	Certain Risks, Concentrations and Uncertainties
	Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash and cash equivalents, restricted cash, investments and receivables. The Company places its cash, cash equivalents and restricted cash with highly rated financial institutions and invests its excess cash in highly rated investments. As of September 30, 2013 and December 31, 2012, approximately $15.7 million, or 17.3%, and $15.6 million, or 18.4%, respectively, of the Company’s cash, cash equivalents, restricted cash and investments were issued or insured by the United States government or United States government agencies. The Company has not experienced any losses on these accounts related to amounts in excess of insured limits.
	The Company’s products and product candidates under development require approval from the FDA or other international regulatory agencies prior to commercial sales. For those product candidates or indications that have not yet been approved by the FDA or international regulatory agencies, there can be no assurance the products will receive the necessary approval. If the Company is denied approval or approval is delayed, it may have a material adverse impact on the Company.
	The Company’s products, AMITIZA and RESCULA, compete in a rapidly changing, highly competitive market, which is characterized by advances in scientific discovery, changes in customer requirements, evolving regulatory requirements, downward pressure on reimbursement pricing, and developing industry standards. Any failure by the Company to anticipate or to respond adequately or timely to these market conditions, or any significant delays in the development or introduction of products could have a material adverse effect on the Company’s business, operating results and future cash flows.
	The Company’s expected activities may necessitate significant uses of working capital. The Company’s working capital requirements will depend on many factors, including the successful sales of AMITIZA and RESCULA, research and development efforts to develop new products or indications, payments received under contractual agreements with other parties, the status of competitive products and market acceptance of the Company’s products by physicians and patients. The Company plans to continue financing operations with its existing cash and investments as well as with product royalty revenue and cash received from milestones and other revenue related to its joint collaboration, license and supply agreements.
	Revenues from Takeda, an unrelated party, accounted for 73.9% and 98.7%, of the Company’s total revenues for the three months ended September 30, 2013 and 2012, respectively, and 82.9% and 98.0% for the nine months ended September 30, 2013 and 2012, respectively. Accounts receivable, unbilled accounts receivable and product royalties receivable from Takeda accounted for 90.9% and 98.0% of the Company’s total accounts receivable, unbilled accounts receivable and product royalties receivable at September 30, 2013 and December 31, 2012, respectively. Revenues from Abbott, another unrelated party, accounted for 24.5% and 0.1% of the Company’s total revenues for the three months ended September 30, 2013 and 2012, respectively, and 16.4% and 1.1% for the nine months ended September 30, 2013 and 2012, respectively. The Company’s revenues depend significantly upon the collaborations with Takeda and Abbott and these revenues may be adversely impacted if these relationships are disrupted.
	The Company has an exclusive supply arrangement with R-Tech to provide the Company with commercial and clinical supplies of its product and product candidates. R-Tech also provides certain preclinical and other research and development services. Any difficulties or delays in performing the services under these arrangements may cause the Company to lose revenues, delay research and development activities or otherwise disrupt the Company’s operations (see Note 8 below).

Note_3_Net_Income_Loss_per_Sha

Note 3 - Net Income (Loss) per Share	9 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Earnings Per Share [Text Block]	'
	3.      Net Income (Loss) per Share
	Basic net income (loss) per share is computed by dividing net income (loss) by the sum of the weighted average class A common shares outstanding. Diluted net income per share is computed by dividing net income by the weighted average common shares and potential dilutive common shares outstanding. Diluted net loss per share, when applicable, is computed by dividing net loss by the weighted average common shares outstanding without the impact of potential dilutive common shares outstanding because they would have an anti-dilutive impact on diluted net loss per share.
	The computation of net income (loss) per share for the three and nine months ended September 30, 2013 and 2012 is shown below:
		Three Months Ended					Nine Months Ended
		September 30,					September 30,
	(In thousands, except per share data)	2013		2012			2013		2012
	Basic net income (loss) per share:
	Net income (loss)	$	1,291	$	(5,949	)	$	4,266	$	(8,696	)
	Weighted average class A and B common shares outstanding		41,863		41,678			41,644		41,697
	Basic net income (loss) per share	$	0.03	$	(0.14	)	$	0.1	$	(0.21	)
	Diluted net income (loss) per share:
	Net income (loss)	$	1,291	$	(5,949	)	$	4,266	$	(8,696	)
	Weighted average class A and B common shares outstanding for diluted net income per share		41,863		41,678			41,644		41,697
	Assumed exercise of stock options under the treasury stock method		924		-			1,018		-
			42,787		41,678			42,662		41,697
	Diluted net income (loss) per share	$	0.03	$	(0.14	)	$	0.1	$	(0.21	)
	The values as of September 30, 2013 and 2012 of the potentially dilutive securities that were used in the calculations of diluted net income per share for the periods listed above are shown below:
		September 30,
	(In thousands)	2013		2012
	Employee stock options		2,374		-
	Non-employee stock options		410		-
	The values as of September 30, 2013 and 2012 of the securities that were excluded from the computation of diluted net loss per share (as their effect would be anti-dilutive) for the periods listed above are shown below:
	(In thousands)	2013		2012
	Employee stock options		576		3,578
	Non-employee stock options		-		450

Note_4_Current_and_NonCurrent_

Note 4 - Current and Non-Current Investments	9 Months Ended
	Sep. 30, 2013
Investments Schedule [Abstract]	'
Investment [Text Block]	'
	4.      Current and Non-Current Investments
	At September 30, 2013 and December 31, 2012, current and non-current available-for-sale investments consisted of the following securities:
		30-Sep-13
	(In thousands)	Cost		Unrealized		Unrealized			Fair Value
				Gains		Losses
	Current:
	U.S. government securities	$	999	$	1	$	-		$	1,000
	U.S. government agencies		9,069		8					9,077
	Certificates of deposits		1,750		-		-			1,750
	Corporate bonds		1,262		-		(1	)		1,261
	Variable rate demand notes		2,175		-		-			2,175
	Total	$	15,255	$	9	$	(1	)	$	15,263
	Non-current:
	U.S. government agencies	$	3,010	$	-	$	(1	)	$	3,009
	Certificates of deposits		4,250		-		-			4,250
	Total	$	7,260	$	-	$	(1	)	$	7,259
		31-Dec-12
	(In thousands)	Cost		Unrealized		Unrealized			Fair Value
				Gains		Losses
	Current:
	U.S. commercial paper	$	2,499	$	-	$	-		$	2,499
	Municipal securities		251		-		-			251
	Certificates of deposits		500		-		-			500
	Variable rate demand notes		2,785		-		-			2,785
	Total	$	6,035	$	-	$	-		$	6,035
	Non-current:
	U.S. government securities	$	10,131	$	2	$	(3	)	$	10,130
	Certificates of deposits		3,000		-		-			3,000
	Corporate bonds		1,281		-		(3	)		1,278
	Total	$	14,412	$	2	$	(6	)	$	14,408
	The Company performs fair value measurements in accordance with the Financial Accounting Standards Board’s guidance for fair value measurements and disclosures, which defines fair value as the exchange price that would be received for selling an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. A fair value hierarchy is established which requires the Company to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The Company classifies its investments into the following categories based on the three levels of inputs used to measure fair value:
	Level 1: quoted prices in active markets for identical assets or liabilities;
	Level 2: inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; or
	Level 3: unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	The Company’s assets measured at fair value on a recurring basis, including cash equivalents, which are subject to the fair value disclosure requirements, at September 30, 2013 and December 31, 2012 are as follows:
		Fair Value Measurements at Reporting Date Using
	30-Sep-13	Quoted Prices		Significant		Significant			Total
	(In thousands)	in Active		Other		Unobservable
		Markets for		Observable		Inputs
		Identical		Inputs		(Level 3)
		Assets		(Level 2)
		(Level 1)
	U.S. government securities	$	-	$	1,000	$	-		$	1,000
	U.S. government agencies		-		12,084					12,084
	U.S. commercial paper		-		6,299		-			6,299
	Certificates of deposits		-		6,000		-			6,000
	Corporate bonds		-		4,012		-			4,012
	Money market funds		6,012		5,115		-			11,127
	Variable rate demand notes		-		2,175		-			2,175
	Total assets measured at fair value	$	6,012	$	36,685	$	-		$	42,697
		Fair Value Measurements at Reporting Date Using
	31-Dec-12	Quoted Prices		Significant		Significant			Total
	(In thousands)	in Active		Other		Unobservable
		Markets for		Observable		Inputs
		Identical		Inputs		(Level 3)
		Assets		(Level 2)
		(Level 1)
	U.S. government securities	$	-	$	10,130	$	-		$	10,130
	U.S. commercial paper		-		5,998		-			5,998
	Municipal securities		-		1,253		-			1,253
	Certificates of deposits		-		3,500		-			3,500
	Corporate bonds		-		6,286		-			6,286
	Money market funds		16,274		-		-			16,274
Variable rate demand notes		-		2,785		-			2,785
Total assets measured at fair value	$	16,274	$	29,952	$	-		$	46,226
If quoted prices in active markets for identical assets and liabilities are not available to determine fair value, then the Company uses quoted prices for similar assets and liabilities or inputs other than the quoted prices that are observable, either directly or indirectly. This pricing methodology applies to the Company’s Level 2 investments.

Note_5_Intangible_Assets

Note 5 - Intangible Assets	9 Months Ended
	Sep. 30, 2013
Disclosure Text Block [Abstract]	'
Intangible Assets Disclosure [Text Block]	'
	5.      Intangible Assets
	In April 2009, the Company entered into a license agreement with R-Tech, or the 2009 R-Tech Agreement, for all patents and other intellectual property rights related to RESCULA for its FDA-approved indication and any new indications for unoprostone isopropyl in the United States and Canada. The Company is commercializing RESCULA (unoprostone isopropyl ophthalmic solution) 0.15% in the United States for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension.
	Under the terms of the 2009 R-Tech Agreement, the Company made an upfront and development payments of $3.5 million and may be required to pay up to $5.0 million in additional milestone payments based on the achievement of specified development and commercialization goals. The Company allocated the acquisition cost between an intangible asset of $3.4 million and a non-current prepaid inventory of $85,000 as of September 30, 2013, which has been expensed during the three months ended September 30, 2013 as shown in the accompanying Condensed Consolidated Balance Sheets. Upon the February 2013 RESCULA re-launch, a $500,000 milestone payment was paid to R-Tech in May 2013. The cost is amortized over the 10-year life of the 2009 R-Tech Agreement, which the Company believes approximates the useful life of the underlying rights and data. Amortization expense was approximately $85,000 for each of the three months ended September 30, 2013 and 2012, and approximately $256,000 for each of the nine months ended September 30, 2013 and 2012. The annual amortization expense will be approximately $341,000 through April 2019. The unamortized amount included in intangible assets was $1.9 million and $2.1 million at September 30, 2013 and December 31, 2012, respectively.
	On March 22, 2011, the Company entered into a license agreement with R-Tech for unoprostone isopropyl, or the 2011 R-Tech Agreement, expanding the Company’s development and commercialization rights as well as its territories beyond the previously agreed territory of the United States and Canada to the rest of the world, with the exception of Japan, Korea, Taiwan and the People’s Republic of China. The Company is now evaluating opportunities to obtain an appropriate label in the European Union and other European countries, and the timing for seeking reauthorization in those countries to commercialize unoprostone isopropyl.
	Pursuant to the 2011 R-Tech Agreement, the Company has made payments to R-Tech of $6.0 million, which is reflected in other non-current assets in the accompanying Condensed Consolidated Balance Sheets, and may be required to pay up to $100.0 million in additional milestone payments to R-Tech based on the achievement of specified development and commercialization goals. The Company will be responsible for all development, regulatory, and commercialization activities. The Company is amortizing the $6.0 million over the 10-year life of the R-Tech Agreement, which the Company believes approximates the useful life of the underlying rights and data. Amortization expense was approximately $153,000 for each of the three months ended September 30, 2013 and 2012, and approximately $460,000 for each of the nine months ended September 30, 2013 and 2012. The annual amortization expense will be approximately $613,000 through March 2021. The unamortized amount included in intangible assets was $4.5 million and $4.9 million at September 30, 2013 and December 31, 2012, respectively.

Note_6_Accrued_Expenses

Note 6 - Accrued Expenses	9 Months Ended
	Sep. 30, 2013
Payables and Accruals [Abstract]	'
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	'
	6.      Accrued Expenses
	Accrued expenses consist of the following as of September 30, 2013 and December 31, 2012:
	(In thousands)	September 30,		December 31,
		2013		2012
	Research and development costs	$	1,929	$	6,662
	Employee compensation		2,469		1,219
	Selling and marketing costs		965		487
	Legal service fees		284		830
	RESCULA milestones		-		500
	Other accrued expenses		564		897
	Total	$	6,211	$	10,595

Note_7_Commitments

Note 7 - Commitments	9 Months Ended
	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	7.      Commitments
	Operating Leases
	The Company leases office space in the United States, Switzerland, Japan and the United Kingdom, under operating leases through 2017. Total future minimum, non-cancelable lease payments under operating leases, are as follows as of September 30, 2013:
	(In thousands of U.S. dollars)	September 30,
		2013
	Remaining 2013	$	371
	2014		1,287
	2015		1,096
	2016		1,084
	2017		139
	Total minimum lease payments	$	3,977
	Rent expense for all operating leases was approximately $323,000 and $426,000 for the three months ended September 30, 2013 and 2012, respectively, and $1.0 million and $1.2 million for the nine months ended September 30, 2013 and 2012, respectively.
	Research and Development Costs
	The Company routinely enters into agreements with third-party contract research organizations to oversee clinical research and development studies provided on an outsourced basis and to assist in other research and development activities. The Company generally is not contractually obligated to pay the third party if the service or reports are not provided. Total future estimated costs through 2015 under these agreements as of September 30, 2013 were approximately $5.9 million.
	The maximum contingent liability under the Numab Agreement (as defined below) in the event that Numab defaults under its loan with Zurcher Kantonalbank is $2.4 million. As of September 30, 2013, the potential amount of payments in the event of Numab’s default is $2.2 million.

Note_8_Related_Party_Transacti

Note 8 - Related Party Transactions	9 Months Ended
	Sep. 30, 2013
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
	8.      Related Party Transactions
	R-Tech Ueno, Ltd.
	In addition to the 2009 R-Tech Agreement and the 2011 R-Tech Agreement described in Note 5 above, the Company is a party to other development and exclusive supply agreements with R-Tech covering various compounds and territories. In the third quarter of 2013, the Company negotiated a reduction in the price of products for Europe, Middle East and Africa. The Company’s founders, Drs. Ryuji Ueno and Sachiko Kuno, directly or indirectly, own a majority of the stock of R-Tech.
	The Company recorded the following expenses under the 2009 R-Tech Agreement and the 2011 R-Tech Agreement for the three and nine months ended September 30, 2013 and 2012:
		Three Months Ended September 30,				Nine Months Ended September 30,
	(In thousands)	2013		2012		2013		2012
	Clinical supplies	$	35	$	331	$	255	$	1,618
	Other research and development services		75		147		181		451
	Commercial supplies		3,173		298		7,906		443
		$	3,283	$	776	$	8,342	$	2,512
	The following table summarizes the amounts included in deferred revenue resulting from the deferral of upfront payments relating to the exclusive supply agreements with R-Tech as of September 30, 2013 and December 31, 2012:
	(In thousands)	September 30,		December 31,
		2013		2012
	Deferred revenue, current	$	373	$	479
	Deferred revenue, non-current		5,128		5,386
		$	5,501	$	5,865
	The Company recognized approximately $105,000 and $112,000 of revenue relating to the 2009 R-Tech Agreement and the 2011 R-Tech Agreement for the three months ended September 30, 2013 and 2012, respectively, and approximately $373,000 and $321,000 for the nine months ended September 30, 2013 and 2012, respectively. Such revenue was recorded as contract and collaboration revenue in the accompanying Condensed Consolidated Statements of Operations and Comprehensive Income (Loss).
	Beginning October 2012, R-Tech is relocating its manufacturing facility for unoprostone isopropyl and will not be able to manufacture and supply unoprostone isopropyl for up to 18 months. R-Tech has designated another facility in Japan for the production of unoprostone isopropyl. However, FDA approval is required before the facility can manufacture unoprostone isopropyl for the United States market, and such facility has been inspected by the FDA in the fourth quarter of 2013. The Company is awaiting the decision by the FDA. In order to mitigate this risk, the Company placed an order of $5.6 million of unoprostone isopropyl to cover this supply period based on the Company’s forecasts for the launch of RESCULA in the United States. R-Tech delivered $5.6 million of that order to the Company in the first and second quarters of 2013. This inventory was substantially written-off as discussed in Note 2 above.
	In addition, R-Tech has a 30-year lease with Ueno Fine Chemicals Industry, LTD., or Ueno Fine Chemical, for the land upon which R-Tech’s manufacturing facility that produces lubiprostone is located. There are approximately 20 years remaining on the lease and R-Tech’s manufacturing facility is on the campus of Ueno Fine Chemical. R-Tech and Ueno Fine Chemical are in litigation in Japan over the terms of the lease including whether or not the lease should be terminated. However, based on information from R-Tech, the Company does not believe that the dispute will adversely affect the supply of lubiprostone.
	Numab AG
	In September 2011, the Company entered into a Loan Guarantee and Development Agreement, or the Numab Agreement, with Numab. Numab is considered a related party as a result of an ownership interest by one of the Company’s former executive officers. Under the terms of the Numab Agreement, the Company would provide Numab with up to CHF 5.0 million as collateral and would serve as guarantor for a loan to Numab from a third party, Zurcher Kantonalbank. Following the payment of the first success fee for its work on the first nominated target during the first quarter of 2013, this amount was reduced to CHF 2.2 million, or approximately $2.4 million as of September 30, 2013.
	As of September 30, 2013, the collateral of CHF 2.2 million has been deposited by the Company and Numab has utilized CHF 2.0 million of its loan facility. During 2012, the Company considered it probable that the success criteria for the first target would be met and made full provision for the success fee. This fee was paid during the first quarter of 2013. In the first quarter of 2013, the Company decided to no longer pursue the further development of the target. In October 2013, Numab and the Company entered into a termination arrangement which will result in continued development by Numab. After successful development by Numab and an agreement with a third party investor, Numab and the Company will enter into a license agreement on commercially reasonable terms. In reviewing the amount outstanding under the loan, and in light of Numab being a start-up company, the Company recorded an additional liability of $153,000 during the third quarter of 2013 in collateral callable to meet a potential loan default by Numab. As of September 30, 2013, the Company has a recorded liability of $512,000 in collateral callable to meet a potential loan default by Numab.

Note_9_Notes_Payable

Note 9 - Notes Payable	9 Months Ended
	Sep. 30, 2013
Debt Disclosure [Abstract]	'
Debt Disclosure [Text Block]	'
	9.      Notes Payable
	In November 2010, the Company’s Japanese subsidiary, Sucampo Pharma Ltd., or SPL, entered into a ¥1,000,000,000 secured term loan agreement with the Tokyo-Mitsubishi Bank. The loan agreement provides for the extension of credit for the period of one year, which can be renewed annually upon the agreement of the Company, SPL and the Tokyo-Mitsubishi Bank. The loan was renewed in November 2012. Borrowings may be used to finance research and development activities, for working capital needs and for the general corporate purposes of SPL. The loan bears annual interest based on the three-month Tokyo Interbank Offer Rate, or TIBOR, plus 1% and is reset quarterly. The interest rate at September 30, 2013 was 1.22%. The outstanding loan balances included in the accompanying Condensed Consolidated Balance Sheets were $10.2 million and $11.6 million as of September 30, 2013 and December 31, 2012, respectively. In connection with the loan agreement, the Company and the Tokyo-Mitsubishi Bank executed a guarantee agreement which provides full guarantee by the Company on behalf of SPL’s obligation to the Tokyo-Mitsubishi Bank. The loan agreement includes representations, covenants, and events of default customary for financing transactions of this type. Additionally, the Company agreed to maintain an amount of collateral that would not fall below 90% of the initial balance throughout the term of the loan. The Company deposited $14.9 million with the Tokyo-Mitsubishi Bank and the deposit bears annual interest of 0.25%, which is recorded as restricted cash, current in the accompanying Condensed Consolidated Balance Sheets as of September 30, 2013 and December 31, 2012. Following the loan renewal in November 2012, and due to the short-term maturity of the agreement, the Company estimated that the carrying value approximated the fair value at September 30, 2013.
	In March 2013, SPL entered into a ¥1,000,000,000 secured term loan agreement with the Mizuho Bank. The loan agreement provides for the extension of credit for the period of one year, which can be renewed annually upon the agreement of the Company, SPL and the Mizuho Bank. Borrowings may be used to finance research and development activities, for working capital needs and for the general corporate purposes of SPL. The loan bears annual interest based on the three-month TIBOR plus 0.25% and is reset quarterly. The interest rate at September 30, 2013 was 0.47%. The outstanding loan balance included in the accompanying Condensed Consolidated Balance Sheets was $10.2 million as of September 30, 2013. The loan agreement includes representations, covenants, and events of default customary for financing transactions of this type. Additionally, SPL agreed to maintain an amount of collateral that would not fall below 100% of the initial balance throughout the term of the loan. SPL deposited $11.0 million with the Mizuho Bank and the deposit bears annual interest of 0.30%, which is recorded as restricted cash, current in the accompanying Condensed Consolidated Balance Sheets as of September 30, 2013. Due to the short-term maturity of the agreement, the Company estimated that the carrying value approximated the fair value at September 30, 2013.
	Subordinated Unsecured Promissory Notes
	In connection with the December 2010 acquisition of Sucampo AG, or SAG, and its wholly owned subsidiary SAG-J, Ambrent Investments S.à.r.l., or Ambrent, issued a subordinated unsecured promissory note, or the notes, to each of the Ueno Trust and Kuno Trust, each a related party of the Company. Each of the notes was issued with an initial principal balance of approximately $25.9 million, or approximately $51.9 million in the aggregate. The interest rate for the notes is the London Interbank Offered Rate, or LIBOR, plus 4.0%, and is reset every six months on December 1st and June 1st of each year. The interest rate beginning June 1, 2013 is 4.4%.
	The notes provide for a semi-annual repayment schedule of interest and principal over a seven-year period on each June 1st and December 1st, provided that until December 1, 2012, all accrued and unpaid interest was not paid in cash and was instead added to the principal balance of the notes and that Ambrent made only two scheduled principal payments on December 1, 2011 and December 1, 2012. Ambrent made the first and second principal payments of $7.5 million each in November 2011 and November 2012, respectively. In May 2013, Ambrent made a principal and interest payment of $4.7 million. Interest expense was approximately $418,000 and $1.3 million for the three and nine months ended September 30, 2013, respectively.
	The notes can be prepaid at any time without penalty. In addition, the notes provide for a mandatory prepayment (i) in full in the event of an acquisition by an unaffiliated third party in an all-cash acquisition of all of the issued and outstanding shares of capital stock of the Company or (ii) either in full or in part in certain change of control transactions involving the Company where an unaffiliated third party acquires a majority of the Company’s voting stock.
	Due to changes in LIBOR rates, the Company has estimated the fair value of the notes payable.
	Notes payable at fair value and carrying value consist of the following at September 30, 2013 and December 31, 2012:
	(In thousands)	Fair Value		December 31,		Carrying Value		December 31,
		September 30,		2012		September 30,		2012
		2013				2013
	Loan agreement, Tokyo-Mitsubishi Bank	$	10,200	$	11,600	$	10,200	$	11,600
	Loan agreement, Mizuho Bank		10,200		-		10,200		-
	Promissory notes, Sellers of SAG		38,346		42,072		37,526		41,251
		$	58,746	$	53,672	$	57,926	$	52,851
	Notes payable, current					$	28,114	$	19,129
	Notes payable, non-current						29,812		33,722
						$	57,926	$	52,851

Note_10_Collaboration_and_Lice

Note 10 - Collaboration and License Agreements	9 Months Ended
	Sep. 30, 2013
Collaborative And License Arrangement Disclosure [Abstract]	'
Collaborative And License Arrangement Disclosure [Text Block]	'
	10.      Collaboration and License Agreements
	Abbott Agreement
	In February 2009, the Company entered into the Abbott Agreement to develop and commercialize lubiprostone for the treatment of CIC in Japan. Additionally, the Abbott Agreement grants Abbott the right of exclusive negotiation to any additional indications for which lubiprostone is developed in Japan under all relevant patents, know-how and trademarks. Under the terms of the Abbott Agreement, payments to the Company include a non-refundable upfront payment and non-refundable development and commercial milestone payments based on achieving specified development, regulatory and sales goals.
	As of September 30, 2013, the Company has received a total of $37.5 million in up-front and development milestone payments under the Abbott Agreement, consisting of a $15.0 million development milestone payment received in December 2012 for the first commercial sale of AMITIZA, as well as $10.0 million and $12.5 million in up-front and development milestone payments, respectively, received in 2009. Under the Abbott Agreement, the Company could receive additional milestone payments based on achieving other specified development and commercialization goals although there can be no assurance that the Company will receive any such payments.
	The following table summarizes the cash streams and related revenue recognized or deferred under the Abbott Agreement for the nine months ended September 30, 2013:
	(In thousands)	Amount		Cash Received		Revenue		Change in			Foreign			Amount
		Deferred at		for the Nine		Recognized for		Accounts			Currency Effects			Deferred at
		December 31,		Months Ended		the Nine		Receivable for			for the Nine			September 30,
		2012		September 30,		Months Ended		the Nine Months			Months Ended			2013
				2013		September 30,		Ended			September 30,
						2013		September 30,			2013
								2013
	Collaboration revenue:
	Up-front payment associated with the Company's	$	725	$	-	$	18	$	-		$	(101	)	$	606
	obligation to participate in joint committees
	Product sales revenue:	$	-	$	9,437	$	10,680	$	1,124		$	119		$	-
	Takeda commercialization and license agreement
	The Company has received a total of $160.0 million in upfront and development milestone payments through September 30, 2013 under the Takeda Agreement, including a $10.0 million development milestone received in the second quarter of 2013 for the first commercial sale of AMITIZA for OIC. Subject to development and acceptance of future indications, the Company is potentially entitled to receive additional development milestone and commercial milestone payments under the Takeda Agreement, although there can be no assurance that the Company will receive any such payments.
	The following table summarizes the cash streams and related revenue recognized or deferred under the Takeda Agreement for the nine months ended September 30, 2013:
	(In thousands)	Amount		Cash Received		Revenue			Change in			Amount
		Deferred at		for the Nine		Recognized for			Accounts			Deferred at
		December 31,		Months Ended		the Nine			Receivable for			September 30,
		2012		September 30,		Months Ended			the Nine Months			2013
				2013		September 30,			Ended
						2013			September 30,
									2013*
	Collaboration revenue:
	Up-front payment associated with the Company's	$	1,176	$	-	$	110	$	-		$	1,066
	obligation to participate in joint committees
	Research and development revenue:
	Up-front payment - remainder	$	-	$	-	$	-	$	-		$	-
	Development milestones		-		10,000		10,000		-			-
	Reimbursement of research and development expenses		249		8,010		6,288		(1,657	)		314
	Total	$	249	$	18,010	$	16,288	$	(1,657	)	$	314
	Product royalty revenue	$	-	$	37,852	$	37,271	$	(581	)		-
	Co-promotion revenue	$	-	$	839	$	61	$	(778	)		-
	*      Includes billed and unbilled accounts receivable.
	Numab AG
	In September 2011, the Company entered into a Loan Guarantee and Development Agreement, or the Numab Agreement, with Numab. Numab is considered a related party as a result of an ownership interest by one of the Company’s former executive officers. Under the terms of the Numab Agreement, the Company would provide Numab with up to CHF 5.0 million as collateral and would serve as guarantor for a loan to Numab from a third party, Zurcher Kantonalbank. Following the payment of the first success fee during the first quarter of 2013, this amount was reduced to CHF 2.2 million, or approximately $2.4 million as of September 30, 2013.
	As of September 30, 2013, the collateral of CHF 2.2 million has been deposited by the Company and Numab has utilized CHF 2.0 million of its loan facility. During 2012, the Company considered it probable that the success criteria for the first target would be met and made full provision for the success fee. This fee was paid during the first quarter of 2013. In the first quarter of 2013, the Company decided to no longer pursue the further development of the target.  In October 2013, Numab and the Company entered into a termination arrangement which will result in continued development by Numab. After successful development by Numab and an agreement with a third party investor, Numab and the Company will enter into a license agreement on commercially reasonable terms. In reviewing the amount outstanding under the loan, and in light of Numab being a start-up company, the Company recorded an additional liability of $153,000 during the third quarter of 2013 in collateral callable to meet a potential loan default by Numab. As of September 30, 2013 the Company has a recorded liability of $512,000 in collateral callable to meet a potential loan default by Numab.

Note_11_Stock_Option_Plans

Note 11 - Stock Option Plans	9 Months Ended
	Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
	11.      Stock Option Plans
	The following table summarizes the employee stock option activity for the nine months ended September 30, 2013 under the Company’s 2001 Incentive Plan:
		Shares			Weighted		Weighted		Aggregate
					Average		Average		Intrinsic Value
					Exercise Price		Remaining
					Per Share		Contractual
							Term (Years)
	Options outstanding, December 31, 2012		156,400		$	10
	Options expired		(10,200	)		10
	Options outstanding, September 30, 2013		146,200			10		2.59	$	-
	Options exercisable, September 30, 2013		146,200			10		2.59	$	-
	The following table summarizes the employee stock option activity for the nine months ended September 30, 2013 under the Company’s Amended and Restated 2006 Stock Incentive Plan:
		Shares			Weighted		Weighted		Aggregate
					Average		Average		Intrinsic Value
					Exercise Price		Remaining
					Per Share		Contractual
							Term (Years)
	Options outstanding, December 31, 2012		3,251,493		$	4.83
	Options granted		204,250			7.36
	Options exercised		(381,595	)		4.37
	Options forfeited		(220,584	)		5.24
	Options expired		(49,965	)		6.61
	Options outstanding, September 30, 2013		2,803,599			5.02		7.66	$	4,522,637
	Options exercisable, September 30, 2013		1,226,384			5.27		7.23	$	1,981,877
	The weighted average grant date fair value of options awarded during the nine months ended September 30, 2013 and the year ended December 31, 2012 was $7.36 and $6.30, respectively. As of September 30, 2013, approximately $1.6 million of total unrecognized compensation costs, net of estimated forfeitures, related to non-vested awards are expected to be recognized over a weighted average period of 1.88 years.
	The following table summarized the non-employee stock option activity for the nine months ended September 30, 2013 under the Company’s 2001 Stock Incentive Plan:
		Shares			Weighted		Weighted		Aggregate
					Average		Average		Intrinsic Value
					Exercise Price		Remaining
					Per Share		Contractual
							Term (Years)
	Options outstanding, December 31, 2012		450,000		$	5.85
	Options exercised		(40,000	)		5.85
	Options outstanding, September 30, 2013		410,000			5.85		1.57	$	159,900
	Options exercisable, September 30, 2013		410,000			5.85		1.57	$	159,900
	Employee Stock Purchase Plan
	Under the Company’s 2006 Employee Stock Purchase Plan, or ESPP, a total of 1,082 and 848 shares of class A common stock were purchased during the three months ended September 30, 2013 and 2012, respectively, and a total of 2,846 and 2,471 shares of class A common stock were purchased during the nine months ended September 30, 2013 and 2012, respectively. The ESPP is non-compensatory and is intended to qualify as an Employee Stock Purchase Plan as defined in Section 423 of the Internal Revenue Code of 1986, as amended, and in accordance with GAAP guidance that requires estimates in the fair value of share-based payment awards on the date of the grant using an option-pricing model and recognizing the expense over the required service periods in the accompanying Condensed Consolidated Statement of Comprehensive Income (Loss). The Company received $6,414 and $4,053 upon the purchase of shares under the ESPP for the three months ended September 30, 2013 and 2012, respectively, and $17,411 and $15,266 upon the purchase of shares under the ESPP for the nine months ended September 30, 2013 and 2012, respectively.

Note_12_Other_income_expense_n

Note 12 - Other income (expense), net	9 Months Ended
	Sep. 30, 2013
Disclosure Text Block [Abstract]	'
Other Nonoperating Income and Expense [Text Block]	'
	12.      Other income (expense), net
	Other income (expense), net consisted of:
		Three Months Ended September 30,					Nine Months Ended September 30,
	(In thousands)	2013			2012		2013		2012
	Exchange gains (losses)	$	(49	)	$	3	$	1,749	$	725
	Other, net		-			5		27		2
		$	(49	)	$	8	$	1,776	$	727
	Other income (expense), net was ($49,000) for the three months ended September 30, 2013, compared to $8,000 for the three months ended September 30, 2012, an increase of $57,000 or 712.5%.  Other income (expense), net was $1.8 million for the nine months ended September 30, 2013, compared to $727,000 for the nine months ended September 30, 2012, an increase of $1.0 million or 144.3%. The increase in other income (expense), net was primarily due to foreign exchange gains in the current period that are unrealized and non-cash and that relate to amounts held within subsidiaries.

Note_13_Income_Taxes

Note 13 - Income Taxes	9 Months Ended
	Sep. 30, 2013
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	13.      Income Taxes
	For the three months ended September 30, 2013 and 2012, the Company recorded a tax benefit of $2.8 million and a tax provision of $3.8 million, respectively. For the nine months ended September 30, 2013 and 2012, the Company recorded a tax provision of $2.6 million and $3.1 million, respectively. The tax benefit for the three months ended September 30, 2013 primarily pertained to pre-tax losses generated by the Company’s United States subsidiary.
	The Company has estimated its annual effective tax rate for the full fiscal year 2013 and 2012 and applied that rate to its income before income taxes in determining its income tax provision for the interim periods. Non-recurring and discrete items that impact tax expense are recorded in the period incurred.
	Tax Benefits
	As of September 30, 2013, the balance of the Company's additional paid-in capital pool related to tax windfall benefits from the stock option exercises was $285,000.
	The Company applies a with-and-without approach in determining its intra-period allocation of tax expense or benefit attributable to stock based compensation deductions. Since the Company does not have any net operating loss carry-forwards in the United States, the tax benefit reduces income taxes payable in the current year and is therefore recorded to additional paid-in-capital.
	Uncertain Tax Positions
	The Company applies the relevant guidance for uncertainty in income taxes that requires the application of a more likely than not threshold to the recognition and derecognition of uncertain tax positions.
	The Company had an outstanding non-current income tax liability of approximately $708,000, including interest, for uncertain tax positions as of September 30, 2013. The amount represented the aggregate tax effect of differences between tax return positions and the amounts otherwise recognized in the Company’s Condensed Consolidated Financial Statements. As of September 30, 2013, $61,000 and $648,000 are reflected as other current liabilities and other liabilities, respectively, in the accompanying Condensed Consolidated Balance Sheets. The liability for uncertain tax positions as of September 30, 2013 mainly pertained to the Company’s interpretation of nexus in certain states related to revenue sourcing for state income tax purposes. During the three months ended September 30, 2013, the liability for income taxes has decreased approximately $77,000. This decrease in the liability is primarily related to the filing of voluntary disclosures and tax returns with various state tax authorities during the quarter offset by an increase related to current year activity in the United States.
	The Company recognizes accrued interest and penalties related to uncertain tax positions as a component of the income tax provision. Other than the expected settlement of state tax liabilities, no additional uncertain tax positions have been identified for which it is reasonably possible that the total amount of liability for unrecognized tax benefits will significantly increase or decrease within 12 months, except for recurring accruals on existing uncertain tax positions. In addition, future changes in the unrecognized tax benefits would have an effect on the effective rate when recognized.

Note_14_Segment_Reporting

Note 14 - Segment Reporting	9 Months Ended
	Sep. 30, 2013
Segment Reporting [Abstract]	'
Segment Reporting Disclosure [Text Block]	'
	14.           Segment Reporting
	The Company has determined that it has three reportable segments based on the Company’s method of internal reporting, which disaggregates business by geographic location. These segments are the Americas, Europe and Asia. The Company evaluates the performance of these segments based on income (loss) from operations, as well as other factors, that depend on the development status of these geographies. Such measures include the progress of its research and development activities, collaboration and licensing efforts, commercialization activities, product sales and other factors. The reportable segments have historically derived their revenue from joint collaboration and strategic alliance agreements. Transactions between the segments consist primarily of loans and the provision of research and development services. The following tables summarize the financial information by reportable geographic segment for the three and nine months ended September 30, 2013 and 2012:
	(In thousands)	Americas			Europe			Asia			Consolidated
	Three Months Ended September 30, 2013
	Research and development revenue	$	2,027		$	-		$	-		$	2,027
	Product royalty revenue		13,595			-			-			13,595
	Product sales revenue		170			17			5,191			5,378
	Co-promotion revenue		-			-			-			-
	Contract and collaboration revenue		141			12			10			163
	Total revenues		15,933			29			5,201			21,163
	Cost of goods sold		3,389			4			2,874			6,267
	Gross profit		12,544			25			2,327			14,896
	Research and development expenses		2,467			1,088			919			4,474
	Depreciation and amortization		309			47			8			364
	Other operating expenses		8,893			1,646			563			11,102
	Income (loss) from operations		875			(2,756	)		837			(1,044	)
	Interest income		18			2			-			20
	Interest expense		-			(417	)		(44	)		(461	)
	Other non-operating expense, net		6			95			(150	)		(49	)
	Income (loss) before income taxes	$	899		$	(3,076	)	$	643		$	(1,534	)
	Capital expenditures	$	9		$	4		$	-		$	13
	Three Months Ended September 30, 2012
	Research and development revenue	$	665		$	72		$	-		$	737
	Product royalty revenue		13,890			-			-			13,890
	Product sales revenue		-			-			-			-
	Co-promotion revenue		730			-			-			730
	Contract and collaboration revenue		141			(15	)		13			139
	Total revenues		15,426			57			13			15,496
	Cost of goods sold		-			-			-			-
	Gross profit		15,426			57			13			15,496
	Research and development expenses		2,239			2,543			833			5,615
	Depreciation and amortization		122			242			10			374
	Other operating expenses		9,677			1,161			322			11,160
	Income (loss) from operations		3,388			(3,889	)		(1,152	)		(1,653	)
	Interest income		65			3			-			68
	Interest expense		-			(556	)		(40	)		(596	)
	Other non-operating expense, net		34			165			(191	)		8
	Income (loss) before income taxes	$	3,487		$	(4,277	)	$	(1,383	)	$	(2,173	)
	Capital expenditures	$	41		$	-		$	-		$	41
	(In thousands)	Americas			Europe			Asia			Consolidated
	Nine Months Ended September 30, 2013
	Research and development revenue	$	16,288		$	-		$	-		$	16,288
	Product royalty revenue		37,271			-			-			37,271
	Product sales revenue		277			37			10,680			10,994
	Co-promotion revenue		61			-			-			61
	Contract and collaboration revenue		424			34			32			490
	Total revenues		54,321			71			10,712			65,104
	Cost of goods sold		3,465			12			5,980			9,457
	Gross profit		50,856			59			4,732			55,647
	Research and development expenses		6,446			4,307			3,775			14,528
	Depreciation and amortization		543			548			26			1,117
	Other operating expenses		27,368			3,374			2,743			33,485
	Income (loss) from operations		16,499			(8,170	)		(1,812	)		6,517
	Interest income		54			8			1			63
	Interest expense		-			(1,326	)		(123	)		(1,449	)
	Other non-operating expense, net		(9	)		(169	)		1,954			1,776
	Income (loss) before income taxes	$	16,544		$	(9,657	)	$	20		$	6,907
	Capital expenditures	$	40		$	110		$	3		$	153
	Nine Months Ended September 30, 2012
	Research and development revenue	$	5,878		$	74		$	466		$	6,418
	Product royalty revenue		36,521			-			-			36,521
	Product sales revenue		-			-			-			-
	Co-promotion revenue		3,253			-			-			3,253
Contract and collaboration revenue		424			(30	)		39			433
Total revenues		46,076			44			505			46,625
Cost of goods sold		-			-			-			-
Gross profit		46,076			44			505			46,625
Research and development expenses		6,250			5,405			2,547			14,202
Depreciation and amortization		366			709			30			1,105
Other operating expenses		32,475			2,576			916			35,967
Income (loss) from operations		6,985			(8,646	)		(2,988	)		(4,649	)
Interest income		105			12			1			118
Interest expense		-			(1,656	)		(124	)		(1,780	)
Other non-operating expense, net		67			82			578			727
Income (loss) before income taxes	$	7,157		$	(10,208	)	$	(2,533	)	$	(5,584	)
Capital expenditures	$	293		$	3,445		$	-		$	3,738
As of September 30, 2013
Property and equipment, net	$	975		$	121		$	182		$	1,278
Identifiable assets, net of intercompany loans
and investments	$	97,915		$	13,420		$	18,385		$	129,720
As of December 31, 2012
Property and equipment, net	$	1,276		$	36		$	228		$	1,540
Identifiable assets, net of intercompany loans
and investments	$	87,731		$	25,465		$	14,600		$	127,796

Accounting_Policies_by_Policy_

Accounting Policies, by Policy (Policies)	9 Months Ended
	Sep. 30, 2013
Accounting Policies [Abstract]	'
Basis of Accounting, Policy [Policy Text Block]	'
	Basis of Presentation
	The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with generally accepted accounting principles in the United States, or GAAP, and the rules and regulations of the Securities and Exchange Commission, or SEC, for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the Company’s Consolidated Financial Statements as of and for the year ended December 31, 2012 included in the Company’s Annual Report on Form 10-K, which was filed with the SEC on March 18, 2013. The financial information as of September 30, 2013 and for the three and nine months ended September 30, 2013 and 2012 is unaudited. In the opinion of the Company’s management, all adjustments, consisting only of normal recurring adjustments or accruals, considered necessary for a fair statement of the results of these interim periods have been included. The results of the Company’s operations for any interim period are not necessarily indicative of the results that may be expected for any other interim period or for a full fiscal year.
	The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries. All significant inter-company balances and transactions have been eliminated.
	The preparation of financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents, Policy [Policy Text Block]	'
	Cash and Cash Equivalents
	For the purpose of the Condensed Consolidated Balance Sheets and Statements of Cash Flows, cash equivalents include all highly liquid investments with a maturity at the time of purchase
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]	'
	Restricted Cash
	Restricted cash primarily represents collateral pledged to support a loan agreement with The Bank of Tokyo-Mitsubishi UFJ, Ltd. (the Tokyo-Mitsubishi Bank); a loan agreement with the Mizuho Bank, Ltd. (the Mizuho Bank); a loan agreement between Numab AG (Numab) and Zurcher Kantonalbank, which we serve as guarantor; and operating leases with certain financial institutions. Restricted cash totaled approximately $28.5 million and $18.9 million at September 30, 2013 and December 31, 2012, respectively.
Investment, Policy [Policy Text Block]	'
	Current and Non-current Investments
	Current and non-current investments consist primarily of United States government agency securities, certificates of deposit, and variable rate demand notes, and are classified as current or non-current based on their maturity dates. The Company classifies all investments as available for-sale-securities and reports unrealized gains or losses, net of related tax effects, in other comprehensive income.
Fair Value of Financial Instruments, Policy [Policy Text Block]	'
	Fair Value of Financial Instruments
	The carrying amounts of the Company’s financial instruments approximate their fair values based on their short maturities, independent valuations or internal assessments. The Company’s financial instruments include cash and cash equivalents, restricted cash, current and non-current investments, receivables, accounts payable and accrued expenses. The Company’s debt is subject to the fair value disclosure requirements as discussed in Note 4 below, and is classified as a Level 2 security.
Accounts Receivable Allowance [Policy Text Block]	'
	Accounts Receivable and Unbilled Accounts Receivable
	Accounts receivable primarily represent amounts due under the Takeda Agreement and the Abbott Agreement. Unbilled accounts receivable consist of research and development expenses that are reimbursable by Takeda, but as of the balance sheet date have not been billed to Takeda. The Company recorded an allowance for doubtful accounts of approximately $426,000 and $280,000 at September 30, 2013 and December 31, 2012, respectively, related to certain disputed Takeda invoices.
Royalty Recognition Policy [Policy Text Block]	'
	Product Royalties Receivable
	Product royalties receivable represent amounts due from Takeda for the Company’s royalties on net sales of AMITIZA, which are based on reports of net sales obtained directly from Takeda.
Inventory, Policy [Policy Text Block]	'
	Inventory
	Inventory is stated at cost or market, whichever is lower. Cost is determined on a first-in, first-out basis. Inventory is reviewed periodically for potential excess, dated or obsolete status. The Company’s management evaluates the carrying value of inventory on a regular basis, taking into account such factors as historical and anticipated future sales compared to quantities on hand, the prices the Company expects to obtain for products in their respective markets compared to historical costs, and the remaining shelf life of goods on hand. During the third quarter of 2013, the Company recorded a $4.5 million non-cash write-off of its RESCULA inventory to reflect anticipated excess quantities of dated product consisting of $3.0 million of product for sale and $1.5 million of sample inventory, compared to nil during the third quarter of 2012. The anticipated excess inventory was largely a result of the necessity to pre-order product in advance of FDA approval due to a planned change in manufacturing facility, and lower than anticipated sales within the useful life of the dated product.  In addition to initial sales falling below their forecast, the Company has recently decided to eliminate its in-house sales force and deploy a contract sales force to detail only current RESCULA prescribers at a much reduced level, which will further impact sales of RESCULA going forward
Revenue Recognition, Policy [Policy Text Block]	'
	Revenue Recognition
	The Company’s revenues are derived primarily from product royalties, development milestone payments, clinical development activities and product sales.
Research and Development Revenue [Policy Text Block]	'
	Research and Development Revenue
	The Company evaluated the multiple deliverables within the collaboration and license agreements in accordance with the guidance of multiple deliverables to determine whether the delivered elements that are the obligation of the Company have value to other parties to the agreement on a stand-alone basis and whether objective reliable evidence of fair value of the undelivered items exists. Deliverables that meet these criteria are considered a separate unit of accounting. Deliverables that do not meet these criteria are combined and accounted for as a single unit of accounting. The appropriate recognition of revenue is then applied to each separate unit of accounting. The Company’s deliverables under the Takeda Agreement and the Abbott Agreement, including the related rights and obligations, contractual cash flows and performance periods, are more fully described in Note 10 below.
Product Royalty Revenue [Policy Text Block]	'
	Product Royalty Revenue
	Royalty revenues are based on net sales of licensed products and are recorded on an accrual basis when earned in accordance with contractual terms if third-party results are reliably measurable, collectability is reasonably assured and all other revenue recognition criteria are met.
Revenue Recognition, Sales of Goods [Policy Text Block]	'
	Product Sales Revenue
	AMITIZA product sales consist of AMITIZA sales to Abbott in Japan and by the Company in Switzerland. Revenue from AMITIZA product sales is recognized when persuasive evidence of an arrangement exists, delivery has occurred, title to product and associated risk of loss have passed to the customer, the price is fixed or determinable, and collection from the customer is reasonably assured. The Company did not record sales deductions and returns for sales of AMITIZA due to the absence of discounts and rebates and the lack of right of return.
	RESCULA product sales consist of RESCULA sales in the United States. The Company recognizes revenue from RESCULA product sales less deductions for estimated sales discounts and sales returns. Revenue from product sales of RESCULA is recognized when persuasive evidence of an arrangement exists, title passes, the price is fixed or determinable, and collectability is reasonably assured. The Company accounts for rebates to certain governmental agencies as a reduction of product sales. The Company allows customers to return product within a specified time period prior to and subsequent to the product’s labeled expiration date. As a result, the Company estimates an accrual for product returns, which is recorded as a reduction of product sales. Given the Company’s limited history of selling RESCULA and the return period, the Company cannot reasonably estimate product returns from the wholesale distribution channel. Therefore, the Company is deferring the recognition of revenue until there is confirmation of pull-through sales to pharmacies or other end user customers. The Company will continue to defer recognition until the point at which the Company has obtained sufficient sales history to reasonably estimate returns from the wholesalers. The Company’s three largest wholesale customers accounted for 98.2% and 95.5% of its RESCULA product sales for the three and nine months ended September 30, 2013, respectively.
Copromotion Revenue Policy Text Block	'
	Co-promotion Revenue
	Co-promotion revenue relates to a limited reimbursement of co-promotion costs based on details to healthcare prescribers.
Contract Revenue Policy Text Block [Policy Text Block]	'
	Contract and Collaboration Revenue
	Contract revenue relates to development and consulting activities and is accounted for under the time-based model.
	The Company considers its participation in joint committees under its collaboration and license agreements as separate deliverables under the contracts and recognizes the fair value of such participation as collaboration revenue over the period of the participation per the terms of the contracts.
	The Company has determined that it is acting as a principal under both the Takeda Agreement and the Abbott Agreement and, as such, records revenue on a gross basis in the Condensed Consolidated Statements of Comprehensive Income (Loss).
Cost of Sales, Policy [Policy Text Block]	'
	Cost of Goods Sold
	Cost of goods sold relates to purchase and distribution costs of the products sold by the Company, including inventory write-offs for excess and obsolete inventory and amortization of marketing licenses.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	'
	Certain Risks, Concentrations and Uncertainties
	Financial instruments that potentially subject the Company to significant concentrations of credit risk consist of cash and cash equivalents, restricted cash, investments and receivables. The Company places its cash, cash equivalents and restricted cash with highly rated financial institutions and invests its excess cash in highly rated investments. As of September 30, 2013 and December 31, 2012, approximately $15.7 million, or 17.3%, and $15.6 million, or 18.4%, respectively, of the Company’s cash, cash equivalents, restricted cash and investments were issued or insured by the United States government or United States government agencies. The Company has not experienced any losses on these accounts related to amounts in excess of insured limits.
	The Company’s products and product candidates under development require approval from the FDA or other international regulatory agencies prior to commercial sales. For those product candidates or indications that have not yet been approved by the FDA or international regulatory agencies, there can be no assurance the products will receive the necessary approval. If the Company is denied approval or approval is delayed, it may have a material adverse impact on the Company.
	The Company’s products, AMITIZA and RESCULA, compete in a rapidly changing, highly competitive market, which is characterized by advances in scientific discovery, changes in customer requirements, evolving regulatory requirements, downward pressure on reimbursement pricing, and developing industry standards. Any failure by the Company to anticipate or to respond adequately or timely to these market conditions, or any significant delays in the development or introduction of products could have a material adverse effect on the Company’s business, operating results and future cash flows.
	The Company’s expected activities may necessitate significant uses of working capital. The Company’s working capital requirements will depend on many factors, including the successful sales of AMITIZA and RESCULA, research and development efforts to develop new products or indications, payments received under contractual agreements with other parties, the status of competitive products and market acceptance of the Company’s products by physicians and patients. The Company plans to continue financing operations with its existing cash and investments as well as with product royalty revenue and cash received from milestones and other revenue related to its joint collaboration, license and supply agreements.
	Revenues from Takeda, an unrelated party, accounted for 73.9% and 98.7%, of the Company’s total revenues for the three months ended September 30, 2013 and 2012, respectively, and 82.9% and 98.0% for the nine months ended September 30, 2013 and 2012, respectively. Accounts receivable, unbilled accounts receivable and product royalties receivable from Takeda accounted for 90.9% and 98.0% of the Company’s total accounts receivable, unbilled accounts receivable and product royalties receivable at September 30, 2013 and December 31, 2012, respectively. Revenues from Abbott, another unrelated party, accounted for 24.5% and 0.1% of the Company’s total revenues for the three months ended September 30, 2013 and 2012, respectively, and 16.4% and 1.1% for the nine months ended September 30, 2013 and 2012, respectively. The Company’s revenues depend significantly upon the collaborations with Takeda and Abbott and these revenues may be adversely impacted if these relationships are disrupted.
	The Company has an exclusive supply arrangement with R-Tech to provide the Company with commercial and clinical supplies of its product and product candidates. R-Tech also provides certain preclinical and other research and development services. Any difficulties or delays in performing the services under these arrangements may cause the Company to lose revenues, delay research and development activities or otherwise disrupt the Company’s operations (see Note 8 below).

Note_3_Net_Income_Loss_per_Sha1

Note 3 - Net Income (Loss) per Share (Tables)	9 Months Ended
	Sep. 30, 2013
Earnings Per Share [Abstract]	'
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	'
		Three Months Ended					Nine Months Ended
		September 30,					September 30,
	(In thousands, except per share data)	2013		2012			2013		2012
	Basic net income (loss) per share:
	Net income (loss)	$	1,291	$	(5,949	)	$	4,266	$	(8,696	)
	Weighted average class A and B common shares outstanding		41,863		41,678			41,644		41,697
	Basic net income (loss) per share	$	0.03	$	(0.14	)	$	0.1	$	(0.21	)
	Diluted net income (loss) per share:
	Net income (loss)	$	1,291	$	(5,949	)	$	4,266	$	(8,696	)
	Weighted average class A and B common shares outstanding for diluted net income per share		41,863		41,678			41,644		41,697
	Assumed exercise of stock options under the treasury stock method		924		-			1,018		-
			42,787		41,678			42,662		41,697
	Diluted net income (loss) per share	$	0.03	$	(0.14	)	$	0.1	$	(0.21	)
Schedule of Potentially Dilutive Securities [Table Text Block]	'
		September 30,
	(In thousands)	2013		2012
	Employee stock options		2,374		-
	Non-employee stock options		410		-
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	'
	(In thousands)	2013		2012
	Employee stock options		576		3,578
	Non-employee stock options		-		450

Note_4_Current_and_NonCurrent_1

Note 4 - Current and Non-Current Investments (Tables)	9 Months Ended
	Sep. 30, 2013
Investments Schedule [Abstract]	'
Available-for-sale Securities [Table Text Block]	'
		30-Sep-13
	(In thousands)	Cost		Unrealized		Unrealized			Fair Value
				Gains		Losses
	Current:
	U.S. government securities	$	999	$	1	$	-		$	1,000
	U.S. government agencies		9,069		8					9,077
	Certificates of deposits		1,750		-		-			1,750
	Corporate bonds		1,262		-		(1	)		1,261
	Variable rate demand notes		2,175		-		-			2,175
	Total	$	15,255	$	9	$	(1	)	$	15,263
	Non-current:
	U.S. government agencies	$	3,010	$	-	$	(1	)	$	3,009
	Certificates of deposits		4,250		-		-			4,250
	Total	$	7,260	$	-	$	(1	)	$	7,259
		31-Dec-12
	(In thousands)	Cost		Unrealized		Unrealized			Fair Value
				Gains		Losses
	Current:
	U.S. commercial paper	$	2,499	$	-	$	-		$	2,499
	Municipal securities		251		-		-			251
	Certificates of deposits		500		-		-			500
	Variable rate demand notes		2,785		-		-			2,785
	Total	$	6,035	$	-	$	-		$	6,035
	Non-current:
	U.S. government securities	$	10,131	$	2	$	(3	)	$	10,130
	Certificates of deposits		3,000		-		-			3,000
	Corporate bonds		1,281		-		(3	)		1,278
	Total	$	14,412	$	2	$	(6	)	$	14,408
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	'
		Fair Value Measurements at Reporting Date Using
	30-Sep-13	Quoted Prices		Significant		Significant			Total
	(In thousands)	in Active		Other		Unobservable
		Markets for		Observable		Inputs
		Identical		Inputs		(Level 3)
		Assets		(Level 2)
		(Level 1)
	U.S. government securities	$	-	$	1,000	$	-		$	1,000
	U.S. government agencies		-		12,084					12,084
	U.S. commercial paper		-		6,299		-			6,299
	Certificates of deposits		-		6,000		-			6,000
	Corporate bonds		-		4,012		-			4,012
	Money market funds		6,012		5,115		-			11,127
	Variable rate demand notes		-		2,175		-			2,175
	Total assets measured at fair value	$	6,012	$	36,685	$	-		$	42,697
		Fair Value Measurements at Reporting Date Using
	31-Dec-12	Quoted Prices		Significant		Significant			Total
	(In thousands)	in Active		Other		Unobservable
		Markets for		Observable		Inputs
		Identical		Inputs		(Level 3)
		Assets		(Level 2)
		(Level 1)
	U.S. government securities	$	-	$	10,130	$	-		$	10,130
	U.S. commercial paper		-		5,998		-			5,998
	Municipal securities		-		1,253		-			1,253
	Certificates of deposits		-		3,500		-			3,500
	Corporate bonds		-		6,286		-			6,286
	Money market funds		16,274		-		-			16,274
	Variable rate demand notes		-		2,785		-			2,785
	Total assets measured at fair value	$	16,274	$	29,952	$	-		$	46,226

Note_6_Accrued_Expenses_Tables

Note 6 - Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2013
Payables and Accruals [Abstract]	'
Schedule of Accrued Liabilities [Table Text Block]	'
	(In thousands)	September 30,		December 31,
		2013		2012
	Research and development costs	$	1,929	$	6,662
	Employee compensation		2,469		1,219
	Selling and marketing costs		965		487
	Legal service fees		284		830
	RESCULA milestones		-		500
	Other accrued expenses		564		897
	Total	$	6,211	$	10,595

Note_7_Commitments_Tables

Note 7 - Commitments (Tables)	9 Months Ended
	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	'
	(In thousands of U.S. dollars)	September 30,
		2013
	Remaining 2013	$	371
	2014		1,287
	2015		1,096
	2016		1,084
	2017		139
	Total minimum lease payments	$	3,977

Note_8_Related_Party_Transacti1

Note 8 - Related Party Transactions (Tables)	9 Months Ended
	Sep. 30, 2013
Related Party Transactions [Abstract]	'
Schedule of Related Party Transactions [Table Text Block]	'
		Three Months Ended September 30,				Nine Months Ended September 30,
	(In thousands)	2013		2012		2013		2012
	Clinical supplies	$	35	$	331	$	255	$	1,618
	Other research and development services		75		147		181		451
	Commercial supplies		3,173		298		7,906		443
		$	3,283	$	776	$	8,342	$	2,512
DeferredRevenueTableTextBlock	'
	(In thousands)	September 30,		December 31,
		2013		2012
	Deferred revenue, current	$	373	$	479
	Deferred revenue, non-current		5,128		5,386
		$	5,501	$	5,865

Note_9_Notes_Payable_Tables

Note 9 - Notes Payable (Tables)	9 Months Ended
	Sep. 30, 2013
Debt Disclosure [Abstract]	'
Schedule of Debt [Table Text Block]	'
	(In thousands)	Fair Value		December 31,		Carrying Value		December 31,
		September 30,		2012		September 30,		2012
		2013				2013
	Loan agreement, Tokyo-Mitsubishi Bank	$	10,200	$	11,600	$	10,200	$	11,600
	Loan agreement, Mizuho Bank		10,200		-		10,200		-
	Promissory notes, Sellers of SAG		38,346		42,072		37,526		41,251
		$	58,746	$	53,672	$	57,926	$	52,851
	Notes payable, current					$	28,114	$	19,129
	Notes payable, non-current						29,812		33,722
						$	57,926	$	52,851

Note_10_Collaboration_and_Lice1

Note 10 - Collaboration and License Agreements (Tables)	9 Months Ended
	Sep. 30, 2013
Abbott [Member]	'
Note 10 - Collaboration and License Agreements (Tables) [Line Items]	'
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]	'
	(In thousands)	Amount		Cash Received		Revenue		Change in			Foreign			Amount
		Deferred at		for the Nine		Recognized for		Accounts			Currency Effects			Deferred at
		December 31,		Months Ended		the Nine		Receivable for			for the Nine			September 30,
		2012		September 30,		Months Ended		the Nine Months			Months Ended			2013
				2013		September 30,		Ended			September 30,
						2013		September 30,			2013
								2013
	Collaboration revenue:
	Up-front payment associated with the Company's	$	725	$	-	$	18	$	-		$	(101	)	$	606
	obligation to participate in joint committees
	Product sales revenue:	$	-	$	9,437	$	10,680	$	1,124		$	119		$	-
Takeda [Member]	'
Note 10 - Collaboration and License Agreements (Tables) [Line Items]	'
Deferred Revenue, by Arrangement, Disclosure [Table Text Block]	'
	(In thousands)	Amount		Cash Received		Revenue			Change in			Amount
		Deferred at		for the Nine		Recognized for			Accounts			Deferred at
		December 31,		Months Ended		the Nine			Receivable for			September 30,
		2012		September 30,		Months Ended			the Nine Months			2013
				2013		September 30,			Ended
						2013			September 30,
									2013*
	Collaboration revenue:
	Up-front payment associated with the Company's	$	1,176	$	-	$	110	$	-		$	1,066
	obligation to participate in joint committees
	Research and development revenue:
	Up-front payment - remainder	$	-	$	-	$	-	$	-		$	-
	Development milestones		-		10,000		10,000		-			-
	Reimbursement of research and development expenses		249		8,010		6,288		(1,657	)		314
	Total	$	249	$	18,010	$	16,288	$	(1,657	)	$	314
	Product royalty revenue	$	-	$	37,852	$	37,271	$	(581	)		-
	Co-promotion revenue	$	-	$	839	$	61	$	(778	)		-

Note_11_Stock_Option_Plans_Tab

Note 11 - Stock Option Plans (Tables)	9 Months Ended
	Sep. 30, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
		Shares			Weighted		Weighted		Aggregate
					Average		Average		Intrinsic Value
					Exercise Price		Remaining
					Per Share		Contractual
							Term (Years)
	Options outstanding, December 31, 2012		156,400		$	10
	Options expired		(10,200	)		10
	Options outstanding, September 30, 2013		146,200			10		2.59	$	-
	Options exercisable, September 30, 2013		146,200			10		2.59	$	-
		Shares			Weighted		Weighted		Aggregate
					Average		Average		Intrinsic Value
					Exercise Price		Remaining
					Per Share		Contractual
							Term (Years)
	Options outstanding, December 31, 2012		3,251,493		$	4.83
	Options granted		204,250			7.36
	Options exercised		(381,595	)		4.37
	Options forfeited		(220,584	)		5.24
	Options expired		(49,965	)		6.61
	Options outstanding, September 30, 2013		2,803,599			5.02		7.66	$	4,522,637
	Options exercisable, September 30, 2013		1,226,384			5.27		7.23	$	1,981,877
		Shares			Weighted		Weighted		Aggregate
					Average		Average		Intrinsic Value
					Exercise Price		Remaining
					Per Share		Contractual
							Term (Years)
	Options outstanding, December 31, 2012		450,000		$	5.85
	Options exercised		(40,000	)		5.85
	Options outstanding, September 30, 2013		410,000			5.85		1.57	$	159,900
	Options exercisable, September 30, 2013		410,000			5.85		1.57	$	159,900

Note_12_Other_income_expense_n1

Note 12 - Other income (expense), net (Tables)	9 Months Ended
	Sep. 30, 2013
Disclosure Text Block [Abstract]	'
Schedule of Other Nonoperating Income (Expense) [Table Text Block]	'
		Three Months Ended September 30,					Nine Months Ended September 30,
	(In thousands)	2013			2012		2013		2012
	Exchange gains (losses)	$	(49	)	$	3	$	1,749	$	725
	Other, net		-			5		27		2
		$	(49	)	$	8	$	1,776	$	727

Note_14_Segment_Reporting_Tabl

Note 14 - Segment Reporting (Tables)	9 Months Ended
	Sep. 30, 2013
Segment Reporting [Abstract]	'
Schedule of Segment Reporting Information, by Segment [Table Text Block]	'
	(In thousands)	Americas			Europe			Asia			Consolidated
	Three Months Ended September 30, 2013
	Research and development revenue	$	2,027		$	-		$	-		$	2,027
	Product royalty revenue		13,595			-			-			13,595
	Product sales revenue		170			17			5,191			5,378
	Co-promotion revenue		-			-			-			-
	Contract and collaboration revenue		141			12			10			163
	Total revenues		15,933			29			5,201			21,163
	Cost of goods sold		3,389			4			2,874			6,267
	Gross profit		12,544			25			2,327			14,896
	Research and development expenses		2,467			1,088			919			4,474
	Depreciation and amortization		309			47			8			364
	Other operating expenses		8,893			1,646			563			11,102
	Income (loss) from operations		875			(2,756	)		837			(1,044	)
	Interest income		18			2			-			20
	Interest expense		-			(417	)		(44	)		(461	)
	Other non-operating expense, net		6			95			(150	)		(49	)
	Income (loss) before income taxes	$	899		$	(3,076	)	$	643		$	(1,534	)
	Capital expenditures	$	9		$	4		$	-		$	13
	Three Months Ended September 30, 2012
	Research and development revenue	$	665		$	72		$	-		$	737
	Product royalty revenue		13,890			-			-			13,890
	Product sales revenue		-			-			-			-
	Co-promotion revenue		730			-			-			730
	Contract and collaboration revenue		141			(15	)		13			139
	Total revenues		15,426			57			13			15,496
	Cost of goods sold		-			-			-			-
	Gross profit		15,426			57			13			15,496
	Research and development expenses		2,239			2,543			833			5,615
	Depreciation and amortization		122			242			10			374
	Other operating expenses		9,677			1,161			322			11,160
	Income (loss) from operations		3,388			(3,889	)		(1,152	)		(1,653	)
	Interest income		65			3			-			68
	Interest expense		-			(556	)		(40	)		(596	)
	Other non-operating expense, net		34			165			(191	)		8
	Income (loss) before income taxes	$	3,487		$	(4,277	)	$	(1,383	)	$	(2,173	)
	Capital expenditures	$	41		$	-		$	-		$	41
	(In thousands)	Americas			Europe			Asia			Consolidated
	Nine Months Ended September 30, 2013
	Research and development revenue	$	16,288		$	-		$	-		$	16,288
	Product royalty revenue		37,271			-			-			37,271
	Product sales revenue		277			37			10,680			10,994
	Co-promotion revenue		61			-			-			61
	Contract and collaboration revenue		424			34			32			490
	Total revenues		54,321			71			10,712			65,104
	Cost of goods sold		3,465			12			5,980			9,457
	Gross profit		50,856			59			4,732			55,647
	Research and development expenses		6,446			4,307			3,775			14,528
	Depreciation and amortization		543			548			26			1,117
	Other operating expenses		27,368			3,374			2,743			33,485
	Income (loss) from operations		16,499			(8,170	)		(1,812	)		6,517
	Interest income		54			8			1			63
	Interest expense		-			(1,326	)		(123	)		(1,449	)
	Other non-operating expense, net		(9	)		(169	)		1,954			1,776
	Income (loss) before income taxes	$	16,544		$	(9,657	)	$	20		$	6,907
	Capital expenditures	$	40		$	110		$	3		$	153
	Nine Months Ended September 30, 2012
	Research and development revenue	$	5,878		$	74		$	466		$	6,418
	Product royalty revenue		36,521			-			-			36,521
	Product sales revenue		-			-			-			-
	Co-promotion revenue		3,253			-			-			3,253
	Contract and collaboration revenue		424			(30	)		39			433
	Total revenues		46,076			44			505			46,625
Cost of goods sold		-			-			-			-
Gross profit		46,076			44			505			46,625
Research and development expenses		6,250			5,405			2,547			14,202
Depreciation and amortization		366			709			30			1,105
Other operating expenses		32,475			2,576			916			35,967
Income (loss) from operations		6,985			(8,646	)		(2,988	)		(4,649	)
Interest income		105			12			1			118
Interest expense		-			(1,656	)		(124	)		(1,780	)
Other non-operating expense, net		67			82			578			727
Income (loss) before income taxes	$	7,157		$	(10,208	)	$	(2,533	)	$	(5,584	)
Capital expenditures	$	293		$	3,445		$	-		$	3,738
As of September 30, 2013
Property and equipment, net	$	975		$	121		$	182		$	1,278
Identifiable assets, net of intercompany loans
and investments	$	97,915		$	13,420		$	18,385		$	129,720
As of December 31, 2012
Property and equipment, net	$	1,276		$	36		$	228		$	1,540
Identifiable assets, net of intercompany loans
and investments	$	87,731		$	25,465		$	14,600		$	127,796

Note_1_Business_Organization_a1

Note 1 - Business Organization and Basis of Presentation (Details)	9 Months Ended
	Sep. 30, 2013
Disclosure Text Block [Abstract]	'
NumberOfProstoneProductsThatReceivedMarketingApproval	2
Number of products in clinical development	2

Note_2_Summary_of_Significant_1

Note 2 - Summary of Significant Accounting Policies (Details) (USD $)

9 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

9 Months Ended

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Jun. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Wholesale [Member]

Wholesale [Member]

Takeda [Member]

Takeda [Member]

Takeda [Member]

Takeda [Member]

Takeda [Member]

Takeda [Member]

Abbott [Member]

Abbott [Member]

Abbott [Member]

Abbott [Member]

RESCULA [Member]

Product for Sale [Member]

Sample Inventory [Member]

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Sales Revenue, Goods, Net [Member]

Sales Revenue, Goods, Net [Member]

Sales Revenue, Goods, Net [Member]

Sales Revenue, Goods, Net [Member]

Accounts Receivable, Unbilled Accounts Receivable and Product Royalties Receivable [Member]

Accounts Receivable, Unbilled Accounts Receivable and Product Royalties Receivable [Member]

Sales Revenue, Goods, Net [Member]

Sales Revenue, Goods, Net [Member]

Sales Revenue, Goods, Net [Member]

Sales Revenue, Goods, Net [Member]

Sales Revenue, Product Line [Member]

Sales Revenue, Product Line [Member]

Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restricted Cash and Cash Equivalents (in Dollars)

$28,500,000

$18,900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Allowance for Doubtful Accounts Receivable (in Dollars)

426,000

280,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Inventory Write-down (in Dollars)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4,500,000

3,000,000

1,500,000

NumberOfWholesalersInConcentrationPercentage

3

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Concentration Risk, Percentage

'

'

98.20%

95.50%

73.90%

98.70%

82.90%

98.00%

90.90%

98.00%

24.50%

0.10%

16.40%

1.10%

'

'

'

Cash, FDIC Insured Amount (in Dollars)

$15,700,000

$15,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

PercentageOfDepositWithinFederallyInsuredLimits

17.30%

18.40%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Note_3_Net_Income_Loss_per_Sha2

Note 3 - Net Income (Loss) per Share (Details) - Computation of Net Income (Loss) Per Share (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Basic net income (loss) per share:	'	'	'	'
Net income (loss) (in Dollars)	$1,291	($5,949)	$4,266	($8,696)
Weighted average class A and B common shares outstanding	41,863	41,678	41,644	41,697
Basic net income (loss) per share (in Dollars per share)	$0.03	($0.14)	$0.10	($0.21)
Diluted net income (loss) per share:	'	'	'	'
Weighted average class A and B common shares outstanding for diluted net income per share	42,787	41,678	42,662	41,697
Diluted net income (loss) per share (in Dollars per share)	$0.03	($0.14)	$0.10	($0.21)
Common Stock [Member]	'	'	'	'
Diluted net income (loss) per share:	'	'	'	'
Weighted average class A and B common shares outstanding for diluted net income per share	41,863	41,678	41,644	41,697
Treasury Stock [Member]	'	'	'	'
Diluted net income (loss) per share:	'	'	'	'
Assumed exercise of stock options under the treasury stock method	924	'	1,018	'

Note_3_Net_Income_Loss_per_Sha3

Note 3 - Net Income (Loss) per Share (Details) - Potentially Dillutive Securities Used in Computation of Diluted Net Income per Share	3 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013
Employee Stock Option [Member]	'
Note 3 - Net Income (Loss) per Share (Details) - Potentially Dillutive Securities Used in Computation of Diluted Net Income per Share [Line Items]	'
Potentially dilutive securities	2,374
Non-Employee Stock Options [Member]	'
Note 3 - Net Income (Loss) per Share (Details) - Potentially Dillutive Securities Used in Computation of Diluted Net Income per Share [Line Items]	'
Potentially dilutive securities	410

Note_3_Net_Income_Loss_per_Sha4

Note 3 - Net Income (Loss) per Share (Details) - Antidilutive Securities Excluded from Computation of Diluted Net loss per Share	3 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012
Employee Stock Options [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive securities	576	3,578
Non-Employee Stock Options [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive securities	'	450

Note_4_Current_and_NonCurrent_2

Note 4 - Current and Non-Current Investments (Details) - Current And Non-Current Investments (USD $)

9 Months Ended

12 Months Ended

9 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

In Thousands, unless otherwise specified

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Dec. 31, 2012

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Dec. 31, 2012

US Government and Government Agencies and Authorities [Member]

US Government and Government Agencies and Authorities [Member]

US Government Agencies Debt Securities [Member]

US Government Agencies Debt Securities [Member]

Certificates of Deposit [Member]

Certificates of Deposit [Member]

Certificates of Deposit [Member]

Certificates of Deposit [Member]

Corporate Bond Securities [Member]

Corporate Bond Securities [Member]

Variable Rate Demand Obligation [Member]

Variable Rate Demand Obligation [Member]

Current [Member]

Current [Member]

Non-current [Member]

Non-current [Member]

Commercial Paper [Member]

Municipal Notes [Member]

Current [Member]

Non-current [Member]

Current [Member]

Current [Member]

Current [Member]

Non-current [Member]

Current [Member]

Non-current [Member]

Current [Member]

Current [Member]

Current [Member]

Current [Member]

Schedule of Available-for-sale Securities [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Cost

$999

$10,131

$9,069

$3,010

$1,750

$500

$3,000

$4,250

$1,262

$1,281

$2,175

$2,785

$6,035

$15,255

$14,412

$7,260

$2,499

$251

Unrealized Losses

'

-3

'

-1

'

'

'

'

-1

-3

'

'

'

-1

-6

-1

'

'

Fair Value

1,000

10,130

9,077

3,009

1,750

500

3,000

4,250

1,261

1,278

2,175

2,785

6,035

15,263

14,408

7,259

2,499

251

Unrealized Gains

$1

$2

$8

'

'

'

'

'

'

'

'

'

'

$9

$2

'

'

'

Note_4_Current_and_NonCurrent_3

Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured At Fair Value On Recurring Basis (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Fair Value, Inputs, Level 1 [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured At Fair Value On Recurring Basis [Line Items]	'	'
Assets at fair value	$6,012	$16,274
Fair Value, Inputs, Level 2 [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured At Fair Value On Recurring Basis [Line Items]	'	'
Assets at fair value	36,685	29,952
Estimate of Fair Value Measurement [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured At Fair Value On Recurring Basis [Line Items]	'	'
Assets at fair value	42,697	46,226
US Government and Government Agencies and Authorities [Member] | Fair Value, Inputs, Level 2 [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured At Fair Value On Recurring Basis [Line Items]	'	'
Assets at fair value	1,000	10,130
US Government and Government Agencies and Authorities [Member] | Estimate of Fair Value Measurement [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured At Fair Value On Recurring Basis [Line Items]	'	'
Assets at fair value	1,000	10,130
US Government Agencies Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured At Fair Value On Recurring Basis [Line Items]	'	'
Assets at fair value	12,084	'
US Government Agencies Debt Securities [Member] | Estimate of Fair Value Measurement [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured At Fair Value On Recurring Basis [Line Items]	'	'
Assets at fair value	12,084	'
Commercial Paper [Member] | Fair Value, Inputs, Level 2 [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured At Fair Value On Recurring Basis [Line Items]	'	'
Assets at fair value	6,299	5,998
Commercial Paper [Member] | Estimate of Fair Value Measurement [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured At Fair Value On Recurring Basis [Line Items]	'	'
Assets at fair value	6,299	5,998
Certificates of Deposit [Member] | Fair Value, Inputs, Level 2 [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured At Fair Value On Recurring Basis [Line Items]	'	'
Assets at fair value	6,000	3,500
Certificates of Deposit [Member] | Estimate of Fair Value Measurement [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured At Fair Value On Recurring Basis [Line Items]	'	'
Assets at fair value	6,000	3,500
Corporate Bond Securities [Member] | Fair Value, Inputs, Level 2 [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured At Fair Value On Recurring Basis [Line Items]	'	'
Assets at fair value	4,012	6,286
Corporate Bond Securities [Member] | Estimate of Fair Value Measurement [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured At Fair Value On Recurring Basis [Line Items]	'	'
Assets at fair value	4,012	6,286
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured At Fair Value On Recurring Basis [Line Items]	'	'
Assets at fair value	6,012	16,274
Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured At Fair Value On Recurring Basis [Line Items]	'	'
Assets at fair value	5,115	'
Money Market Funds [Member] | Estimate of Fair Value Measurement [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured At Fair Value On Recurring Basis [Line Items]	'	'
Assets at fair value	11,127	16,274
Variable Rate Demand Obligation [Member] | Fair Value, Inputs, Level 2 [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured At Fair Value On Recurring Basis [Line Items]	'	'
Assets at fair value	2,175	2,785
Variable Rate Demand Obligation [Member] | Estimate of Fair Value Measurement [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured At Fair Value On Recurring Basis [Line Items]	'	'
Assets at fair value	2,175	2,785
Municipal Notes [Member] | Fair Value, Inputs, Level 2 [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured At Fair Value On Recurring Basis [Line Items]	'	'
Assets at fair value	'	1,253
Municipal Notes [Member] | Estimate of Fair Value Measurement [Member]	'	'
Note 4 - Current and Non-Current Investments (Details) - Companybs Assets Measured At Fair Value On Recurring Basis [Line Items]	'	'
Assets at fair value	'	$1,253

Note_5_Intangible_Assets_Detai

Note 5 - Intangible Assets (Details) (USD $)	1 Months Ended	3 Months Ended		4 Months Ended	9 Months Ended
	30-May-13	Sep. 30, 2013	Sep. 30, 2012	Apr. 30, 2009	Sep. 30, 2013	Sep. 30, 2012
Note 5 - Intangible Assets (Details) [Line Items]	'	'	'	'	'	'
Payments to Acquire Intangible Assets	'	'	'	'	'	$3,000,000
Amortization of Intangible Assets	'	'	153,000	'	'	'
2009 R-Tech Agreement [Member]	'	'	'	'	'	'
Note 5 - Intangible Assets (Details) [Line Items]	'	'	'	'	'	'
Payments to Acquire Intangible Assets	'	'	'	3,500,000	'	'
MilestonePaymentsMaximumAmount	'	'	'	5,000,000	'	'
Finite-lived Intangible Assets Acquired	'	'	'	'	3,400,000	'
MilestonePayments	500,000	'	'	'	'	'
Finite-Lived Intangible Asset, Useful Life	'	'	'	'	'10 years	'
Amortization of Intangible Assets	'	85,000	85,000	'	256,000	256,000
FiniteLivedIntangibleAssetsAmortizationExpensePerPeriod	'	'	'	'	341,000	'
Finite-Lived Intangible Assets, Net	'	1,900,000	2,100,000	'	1,900,000	2,100,000
2011 R-Tech Agreement [Member]	'	'	'	'	'	'
Note 5 - Intangible Assets (Details) [Line Items]	'	'	'	'	'	'
Payments to Acquire Intangible Assets	'	'	'	'	6,000,000	'
MilestonePaymentsMaximumAmount	'	100,000,000	'	'	100,000,000	'
Finite-lived Intangible Assets Acquired	'	'	'	'	6,000,000	'
Finite-Lived Intangible Asset, Useful Life	'	'	'	'	'10 years	'
Amortization of Intangible Assets	'	153,000	'	'	460,000	460,000
FiniteLivedIntangibleAssetsAmortizationExpensePerPeriod	'	'	'	'	613,000	'
Finite-Lived Intangible Assets, Net	'	4,500,000	4,900,000	'	4,500,000	4,900,000
2009 R-Tech Agreement [Member]	'	'	'	'	'	'
Note 5 - Intangible Assets (Details) [Line Items]	'	'	'	'	'	'
Inventory, Noncurrent	'	$85,000	'	'	$85,000	'

Note_6_Accrued_Expenses_Detail

Note 6 - Accrued Expenses (Details) - Accrued Expenses (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Accrued Expenses [Abstract]	'	'
Research and development costs	$1,929	$6,662
Employee compensation	2,469	1,219
Selling and marketing costs	965	487
Legal service fees	284	830
RESCULA milestones	'	500
Other accrued expenses	564	897
Total	$6,211	$10,595

Note_7_Commitments_Details

Note 7 - Commitments (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Note 7 - Commitments (Details) [Line Items]	'	'	'	'
Operating Leases, Rent Expense	$323,000	$426,000	$1,000,000	$1,200,000
ResearchAndDevelopmentCosts	'	'	5,900,000	'
Guarantee of Indebtedness of Others [Member]	'	'	'	'
Note 7 - Commitments (Details) [Line Items]	'	'	'	'
Loss Contingency, Range of Possible Loss, Maximum	2,400,000	'	2,400,000	'
Loss Contingency, Estimate of Possible Loss	$2,200,000	'	$2,200,000	'

Note_7_Commitments_Details_Fut

Note 7 - Commitments (Details) - Future Minimum, Non-Cancelable Lease Payments (USD $)	Sep. 30, 2013
In Thousands, unless otherwise specified
Future Minimum, Non-Cancelable Lease Payments [Abstract]	'
Remaining 2013	$371
2014	1,287
2015	1,096
2016	1,084
2017	139
Total minimum lease payments	$3,977

Note_8_Related_Party_Transacti2

Note 8 - Related Party Transactions (Details)

3 Months Ended

9 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2011

Sep. 30, 2011

Sep. 30, 2013

Oct. 31, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Jun. 30, 2013

Mar. 31, 2013

Guarantee of Indebtedness of Others [Member]

Guarantee of Indebtedness of Others [Member]

Numab Agreement [Member]

Numab Agreement [Member]

Numab Agreement [Member]

Numab Agreement [Member]

Numab Agreement [Member]

Numab Agreement [Member]

R-Tech [Member]

R-Tech [Member]

R-Tech [Member]

R-Tech [Member]

R-Tech [Member]

R-Tech [Member]

R-Tech [Member]

R-Tech [Member]

USD ($)

USD ($)

Restricted Cash [Member]

Zurcher Kantonalbank [Member]

USD ($)

CHF

Maximum [Member]

Maximum [Member]

Ueno Fine Chemical [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

CHF

USD ($)

CHF

Note 8 - Related Party Transactions (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Contracts Revenue

'

'

'

'

'

'

'

'

'

'

$105,000

$112,000

$373,000

$321,000

'

'

Manufacture and Supply Period of Inactivity of Certain Product

'

'

'

'

'

'

'

'

'

'18 months

'

'

'

'

'

'

Purchase Commitment, Remaining Minimum Amount Committed

'

'

'

'

'

'

'

'

'

5,600,000

'

'

'

'

'

'

SignificantPurchaseCommitmentSatisfiedAmount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,600,000

5,600,000

Lease Term

'

'

'

'

'

'

'

'

'30 years

'

'

'

'

'

'

'

Remaining Lease Term

'

'

'

'

'

'

'

'

'20 years

'

'

'

'

'

'

'

Loans Pledged as Collateral (in Francs)

'

'

2,400,000

2,200,000

2,400,000

2,200,000

5,000,000

5,000,000

'

'

'

'

'

'

'

'

Loans Pledged as Collateral

'

'

2,400,000

2,200,000

2,400,000

2,200,000

5,000,000

5,000,000

'

'

'

'

'

'

'

'

Loans Pledged as Collateral, Amount Deposited (in Francs)

'

'

'

'

'

2,200,000

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Face Amount (in Francs)

'

'

'

'

'

2,000,000

'

'

'

'

'

'

'

'

'

'

Loss Contingency Accrual, Provision

$153,000

$512,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Note_8_Related_Party_Transacti3

Note 8 - Related Party Transactions (Details) - Expenses Under Agreements With R-Tech (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Related Party Transaction [Line Items]	'	'	'	'
Expenses related to R-Tech	$3,283	$776	$8,342	$2,512
Clinical Supplies [Member]	'	'	'	'
Related Party Transaction [Line Items]	'	'	'	'
Expenses related to R-Tech	35	331	255	1,618
Other research and development services [Member]	'	'	'	'
Related Party Transaction [Line Items]	'	'	'	'
Expenses related to R-Tech	75	147	181	451
Commercial supplies [Member]	'	'	'	'
Related Party Transaction [Line Items]	'	'	'	'
Expenses related to R-Tech	$3,173	$298	$7,906	$443

Note_8_Related_Party_Transacti4

Note 8 - Related Party Transactions (Details) - Amounts Included In Deferred Revenue Resulting From Deferral Of Upfront Payments Relating To Exclusive Supply Agreements With R-Tech (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Note 8 - Related Party Transactions (Details) - Amounts Included In Deferred Revenue Resulting From Deferral Of Upfront Payments Relating To Exclusive Supply Agreements With R-Tech [Line Items]	'	'
Deferred revenue, current	$1,148	$3,700
Deferred revenue, non-current	6,490	7,093
R-Tech [Member] | Purchase Commitment [Member]	'	'
Note 8 - Related Party Transactions (Details) - Amounts Included In Deferred Revenue Resulting From Deferral Of Upfront Payments Relating To Exclusive Supply Agreements With R-Tech [Line Items]	'	'
Deferred revenue, current	373	479
Deferred revenue, non-current	5,128	5,386
	$5,501	$5,865

Note_9_Notes_Payable_Details

Note 9 - Notes Payable (Details)

1 Months Ended

1 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

Nov. 30, 2012

Dec. 31, 2010

Dec. 31, 2010

Nov. 30, 2010

Sep. 30, 2013

Dec. 31, 2012

Mar. 31, 2013

Sep. 30, 2013

31-May-13

Nov. 30, 2011

Nov. 30, 2010

Dec. 31, 2010

Dec. 31, 2010

Sep. 30, 2013

Sep. 30, 2013

Jun. 01, 2013

USD ($)

Ueno Trust [Member]

Kuno and Ueno Trust [Member]

Tokyo-Mitsubishi Bank [Member]

Tokyo-Mitsubishi Bank [Member]

Tokyo-Mitsubishi Bank [Member]

Mizuho Bank Limited [Member]

Mizuho Bank Limited [Member]

Kuno and Ueno Trust [Member]

Kuno and Ueno Trust [Member]

TIBOR [Member]

London Interbank Offered Rate (LIBOR) [Member]

Subordinated Unsecured Promissory Notes [Member]

Subordinated Unsecured Promissory Notes [Member]

Subordinated Unsecured Promissory Notes [Member]

Subordinated Unsecured Promissory Notes [Member]

Subordinated Unsecured Promissory Notes [Member]

Subordinated Unsecured Promissory Notes [Member]

Secured Debt [Member]

Secured Debt [Member]

Secured Debt [Member]

Secured Debt [Member]

Secured Debt [Member]

Subordinated Unsecured Promissory Notes [Member]

Subordinated Unsecured Promissory Notes [Member]

Subordinated Unsecured Promissory Notes [Member]

USD ($)

USD ($)

USD ($)

USD ($)

JPY (¥)

USD ($)

USD ($)

JPY (¥)

USD ($)

USD ($)

USD ($)

Note 9 - Notes Payable (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Maximum Borrowing Capacity (in Yen)

'

'

'

¥ 1,000,000,000

'

'

¥ 1,000,000,000

'

'

'

'

'

'

'

'

'

LineOfCreditFacilityPotentialTermExtensionPeriod

'

'

'

'1 year

'

'

'1 year

'

'

'

'

'

'

'

'

'

Debt Instrument, Basis Spread on Variable Rate

'

'

'

'

'

'

0.25%

'

'

'

1.00%

4.00%

'

'

'

'

Line of Credit Facility, Interest Rate at Period End

'

'

'

'

1.22%

'

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Amount Outstanding

'

'

'

'

10,200,000

11,600,000

'

10,200,000

'

'

'

'

'

'

'

'

PercentageCollateralToLoans

'

'

'

90.00%

'

'

'

100.00%

'

'

'

'

'

'

'

'

Interest-bearing Deposits in Banks and Other Financial Institutions

'

'

'

'

14,900,000

'

'

11,000,000

'

'

'

'

'

'

'

'

Weighted Average Rate Domestic Deposit

'

'

'

'

0.25%

'

'

0.30%

'

'

'

'

'

'

'

'

Line of Credit Facility, Interest Rate Description

'

'

'

'

'

'

'The loan bears annual interest based on the three-month TIBOR plus 0.25% and is reset quarterly.

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Interest Rate During Period

'

'

'

'

'

'

'

0.47%

'

'

'

'

'

'

'

'

Debt Instrument, Face Amount

'

25,900,000

51,900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Interest Rate, Stated Percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

4.40%

DebtInstrumentLengthOfAgreement

'

'

'

'

'

'

'

'

'

'

'

'

'7 years

'

'

'

InterestRateEffectiveDate

'

'

'

'

'

'

'

'

'

'

'

'

31-Dec-11

'

'

'

Repayments of Notes Payable

7,500,000

'

'

'

'

'

'

'

4,700,000

7,500,000

'

'

'

'

'

'

Interest Expense, Debt

'

'

'

'

'

'

'

'

'

'

'

'

'

$418,000

$1,300,000

'

Note_9_Notes_Payable_Details_C

Note 9 - Notes Payable (Details) - Components of Notes Payable (USD $)	Sep. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Note 9 - Notes Payable (Details) - Components of Notes Payable [Line Items]	'	'
Note Payable Fair Value	$58,746	$53,672
Note Payable Carrying Value	57,926	52,851
Notes payable, current	28,114	19,129
Notes payable, non-current	29,812	33,722
Tokyo-Mitsubishi Bank [Member]	'	'
Note 9 - Notes Payable (Details) - Components of Notes Payable [Line Items]	'	'
Note Payable Fair Value	10,200	11,600
Note Payable Carrying Value	10,200	11,600
Mizuho Bank Limited [Member]	'	'
Note 9 - Notes Payable (Details) - Components of Notes Payable [Line Items]	'	'
Note Payable Fair Value	10,200	'
Note Payable Carrying Value	10,200	'
SAG [Member]	'	'
Note 9 - Notes Payable (Details) - Components of Notes Payable [Line Items]	'	'
Note Payable Fair Value	38,346	42,072
Note Payable Carrying Value	$37,526	$41,251

Note_10_Collaboration_and_Lice2

Note 10 - Collaboration and License Agreements (Details)

3 Months Ended

9 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2013

Dec. 31, 2012

Dec. 31, 2009

Jun. 30, 2013

Dec. 31, 2009

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2011

Sep. 30, 2011

Guarantee of Indebtedness of Others [Member]

Guarantee of Indebtedness of Others [Member]

Up Front Fee And Milestone Payment Arrangement [Member]

Up Front Fee And Milestone Payment Arrangement [Member]

Milestone Payment Arrangement [Member]

Milestone Payment Arrangement [Member]

Milestone Payment Arrangement [Member]

Up-front Payment Arrangement [Member]

Numab Agreement [Member]

Numab Agreement [Member]

Numab Agreement [Member]

Numab Agreement [Member]

USD ($)

USD ($)

Abbott [Member]

Takeda [Member]

Abbott [Member]

Abbott [Member]

Takeda [Member]

Abbott [Member]

USD ($)

CHF

Maximum [Member]

Maximum [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

CHF

Note 10 - Collaboration and License Agreements (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Revenue Recognition, Milestone Method, Revenue Recognized

'

'

$37,500,000

$160,000,000

$15,000,000

$12,500,000

$10,000,000

$10,000,000

'

'

'

'

Loans Pledged as Collateral

'

'

'

'

'

'

'

'

2,400,000

2,200,000

5,000,000

5,000,000

Loans Pledged as Collateral (in Francs)

'

'

'

'

'

'

'

'

2,400,000

2,200,000

5,000,000

5,000,000

Loans Pledged as Collateral, Amount Deposited (in Francs)

'

'

'

'

'

'

'

'

'

2,200,000

'

'

Debt Instrument, Face Amount (in Francs)

'

'

'

'

'

'

'

'

'

2,000,000

'

'

Loss Contingency Accrual, Provision

$153,000

$512,000

'

'

'

'

'

'

'

'

'

'

Note_10_Collaboration_and_Lice3

Note 10 - Collaboration and License Agreements (Details) - Cash Streams And Related Revenue Recognized Or Deferred Under Collaborative Agreements (Abbott [Member], USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013
Collaborative Arrangement [Member]	'
Deferred Revenue Arrangement [Line Items]	'
Amount Deferred	$725
Revenue Recognized	18
Foreign Currency Effects	-101
Amount Deferred	606
Product Sales Revenue [Member]	'
Deferred Revenue Arrangement [Line Items]	'
Cash Received	9,437
Revenue Recognized	10,680
Change in Accounts Receivable	1,124
Foreign Currency Effects	$119

Note_10_Collaboration_and_Lice4

Note 10 - Collaboration and License Agreements (Details) - Cash Streams And Related Revenue Recognized Or Deferred Under Takeda Agreement (Takeda [Member], USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013		Dec. 31, 2012
Development Milestone [Member] | Research And Development Revenue [Member]	'		'
Deferred Revenue Arrangement [Line Items]	'		'
Cash Received	$10,000		'
Revenue Recognized	10,000		'
Change in Accounts Receivable	'	[1]	'
Reimbursement Of Research And Development Expenses [Member] | Research And Development Revenue [Member]	'		'
Deferred Revenue Arrangement [Line Items]	'		'
Amount Deferred	314		249
Cash Received	8,010		'
Revenue Recognized	6,288		'
Change in Accounts Receivable	-1,657	[1]	'
Collaborative Arrangement [Member]	'		'
Deferred Revenue Arrangement [Line Items]	'		'
Amount Deferred	1,066		1,176
Revenue Recognized	110		'
Change in Accounts Receivable	'	[1]	'
Up Front Payment Remainder [Member]	'		'
Deferred Revenue Arrangement [Line Items]	'		'
Change in Accounts Receivable	'	[1]	'
Research And Development Revenue [Member]	'		'
Deferred Revenue Arrangement [Line Items]	'		'
Amount Deferred	314		249
Cash Received	18,010		'
Revenue Recognized	16,288		'
Change in Accounts Receivable	-1,657	[1]	'
Product Royalty Revenue [Member]	'		'
Deferred Revenue Arrangement [Line Items]	'		'
Cash Received	37,852		'
Revenue Recognized	37,271		'
Change in Accounts Receivable	-581	[1]	'
Co-promotion revenue [Member]	'		'
Deferred Revenue Arrangement [Line Items]	'		'
Cash Received	839		'
Revenue Recognized	61		'
Change in Accounts Receivable	($778)	[1]	'
[1]	Includes billed and unbilled accounts receivable.

Note_11_Stock_Option_Plans_Det

Note 11 - Stock Option Plans (Details) (USD $)	9 Months Ended		12 Months Ended	3 Months Ended		9 Months Ended		3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
				2006 Employee Stock Purchase Plan [Member]	2006 Employee Stock Purchase Plan [Member]	2006 Employee Stock Purchase Plan [Member]	2006 Employee Stock Purchase Plan [Member]	Common Class A [Member]	Common Class A [Member]	Common Class A [Member]	Common Class A [Member]
								2006 Employee Stock Purchase Plan [Member]	2006 Employee Stock Purchase Plan [Member]	2006 Employee Stock Purchase Plan [Member]	2006 Employee Stock Purchase Plan [Member]
Note 11 - Stock Option Plans (Details) [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)	$7.36	'	$6.30	'	'	'	'	'	'	'	'
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$1,600,000	'	'	'	'	'	'	'	'	'	'
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	'1 year 321 days	'	'	'	'	'	'	'	'	'	'
Stock Issued During Period, Shares, Employee Stock Purchase Plans (in Shares)	'	'	'	'	'	'	'	1,082	848	2,846	2,471
Proceeds from Stock Options Exercised	$1,543,000	$67,000	'	$6,414	$4,053	$17,411	$15,266	'	'	'	'

Note_11_Stock_Option_Plans_Det1

Note 11 - Stock Option Plans (Details) - Employee Stock Option Activity (USD $)	9 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Employee Stock Plan 2001 [Member]	'	'
Note 11 - Stock Option Plans (Details) - Employee Stock Option Activity [Line Items]	'	'
Options Outstanding	146,200	156,400
Options Outstanding, Weighted Average Exercise Price Per Share (in Dollars per share)	$10	$10
Options Outstanding, Weighted Average Remaining Contractual Term (Years)	'2 years 215 days	'
Options exercisable	146,200	'
Options exercisable, Weighted Average Exercise Price Per Share (in Dollars per share)	$10	'
Options exercisable, Weighted Average Remaining Contractual Term (Years)	'2 years 215 days	'
Options expired	-10,200	'
Options expired, Weighted Average Exercise Price Per Share (in Dollars per share)	$10	'
Stock Incentive Plan 2006 [Member]	'	'
Note 11 - Stock Option Plans (Details) - Employee Stock Option Activity [Line Items]	'	'
Options Outstanding	2,803,599	3,251,493
Options Outstanding, Weighted Average Exercise Price Per Share (in Dollars per share)	$5.02	$4.83
Options Outstanding, Weighted Average Remaining Contractual Term (Years)	'7 years 240 days	'
Options Outstanding, Aggregate Intrinsic Value (in Dollars)	$4,522,637	'
Options granted	204,250	'
Options granted (in Dollars per share)	$7.36	'
Options exercised	-381,595	'
Options exercised, Weighted Average Exercise Price Per Share (in Dollars per share)	$4.37	'
Options forfeited	-220,584	'
Options forfeited (in Dollars per share)	$5.24	'
Options exercisable	1,226,384	'
Options exercisable, Weighted Average Exercise Price Per Share (in Dollars per share)	$5.27	'
Options exercisable, Weighted Average Remaining Contractual Term (Years)	'7 years 83 days	'
Options exercisable, Aggregate Intrinsic Value (in Dollars)	1,981,877	'
Options expired	-49,965	'
Options expired, Weighted Average Exercise Price Per Share (in Dollars per share)	$6.61	'
Non Employee Stock Plan 2001 [Member]	'	'
Note 11 - Stock Option Plans (Details) - Employee Stock Option Activity [Line Items]	'	'
Options Outstanding	410,000	450,000
Options Outstanding, Weighted Average Exercise Price Per Share (in Dollars per share)	$5.85	$5.85
Options Outstanding, Weighted Average Remaining Contractual Term (Years)	'1 year 208 days	'
Options Outstanding, Aggregate Intrinsic Value (in Dollars)	159,900	'
Options exercised	-40,000	'
Options exercised, Weighted Average Exercise Price Per Share (in Dollars per share)	$5.85	'
Options exercisable	410,000	'
Options exercisable, Weighted Average Exercise Price Per Share (in Dollars per share)	$5.85	'
Options exercisable, Weighted Average Remaining Contractual Term (Years)	'1 year 208 days	'
Options exercisable, Aggregate Intrinsic Value (in Dollars)	$159,900	'

Note_12_Other_income_expense_n2

Note 12 - Other income (expense), net (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Note 12 - Other income (expense), net (Details) [Line Items]	'	'	'	'
Other Nonoperating Income (Expense)	($49,000)	$8,000	$1,776,000	$727,000
Other Nonoperating Income Expense Percent Increase	712.50%	'	144.30%	'
Increase [Member]	'	'	'	'
Note 12 - Other income (expense), net (Details) [Line Items]	'	'	'	'
Other Nonoperating Income (Expense)	$57,000	'	$1,800,000	$1,000,000

Note_12_Other_income_expense_n3

Note 12 - Other income (expense), net (Details) - Summary Other Income (Expense), Net (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Note 12 - Other income (expense), net (Details) - Summary Other Income (Expense), Net [Line Items]	'	'	'	'
Other Income (Expense), Net	($49,000)	$8,000	$1,776,000	$727,000
Exchange Gains (Losses) [Member]	'	'	'	'
Note 12 - Other income (expense), net (Details) - Summary Other Income (Expense), Net [Line Items]	'	'	'	'
Other Income (Expense), Net	-49,000	3,000	1,749,000	725,000
Other, Net [Member]	'	'	'	'
Note 12 - Other income (expense), net (Details) - Summary Other Income (Expense), Net [Line Items]	'	'	'	'
Other Income (Expense), Net	'	$5,000	$27,000	$2,000

Note_13_Income_Taxes_Details

Note 13 - Income Taxes (Details) (USD $)	3 Months Ended		6 Months Ended	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2012
Note 13 - Income Taxes (Details) [Line Items]	'	'	'	'	'
Income Tax Expense (Benefit)	($2,825,000)	$3,776,000	'	$2,641,000	$3,112,000
Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation	'	'	'	-304,000	'
Liability for Uncertain Tax Positions, Noncurrent	708,000	'	708,000	708,000	'
Increase (Decrease) in Deferred Income Taxes	'	'	77,000	'	'
Employee Stock Option [Member]	'	'	'	'	'
Note 13 - Income Taxes (Details) [Line Items]	'	'	'	'	'
Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation	'	'	'	285,000	'
Other Current Liabilities [Member]	'	'	'	'	'
Note 13 - Income Taxes (Details) [Line Items]	'	'	'	'	'
Liability for Uncertain Tax Positions, Noncurrent	61,000	'	61,000	61,000	'
Other Liabilities [Member]	'	'	'	'	'
Note 13 - Income Taxes (Details) [Line Items]	'	'	'	'	'
Liability for Uncertain Tax Positions, Noncurrent	$648,000	'	$648,000	$648,000	'

Note_14_Segment_Reporting_Deta

Note 14 - Segment Reporting (Details)	9 Months Ended
	Sep. 30, 2013
Segment Reporting [Abstract]	'
Number of Reportable Segments	3

Note_14_Segment_Reporting_Deta1

Note 14 - Segment Reporting (Details) - Financial Information By Reportable Geographic Segment (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Segment Reporting Information [Line Items]	'	'	'	'	'
Research and development revenue	$2,027,000	$737,000	$16,288,000	$6,418,000	'
Product royalty revenue	13,595,000	13,890,000	37,271,000	36,521,000	'
Product sales revenue	5,378,000	'	10,994,000	'	'
Co-promotion revenue	'	730,000	61,000	3,253,000	'
Contract and collaboration revenue	163,000	139,000	490,000	433,000	'
Total revenues	21,163,000	15,496,000	65,104,000	46,625,000	'
Cost of goods sold	6,267,000	'	9,457,000	'	'
Gross profit	14,896,000	15,496,000	55,647,000	46,625,000	'
Research and development expenses	4,474,000	5,615,000	14,528,000	14,202,000	'
Depreciation and amortization	364,000	374,000	1,117,000	1,105,000	'
Other operating expenses	11,102,000	11,160,000	33,485,000	35,967,000	'
Income (loss) from operations	-1,044,000	-1,653,000	6,517,000	-4,649,000	'
Interest income	20,000	68,000	63,000	118,000	'
Interest expense	-461,000	-596,000	-1,449,000	-1,780,000	'
Other non-operating expense, net	-49,000	8,000	1,776,000	727,000	'
Income (loss) before income taxes	-1,534,000	-2,173,000	6,907,000	-5,584,000	'
Capital expenditures	13,000	41,000	153,000	3,738,000	'
Property and equipment, net	1,278,000	'	1,278,000	'	1,540,000
Identifiable assets, net of intercompany loans	'	'	'	'	'
Identifiable assets, net of intercompany loans and investments	129,720,000	'	129,720,000	'	127,796,000
Americas [Member]	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Research and development revenue	2,027,000	665,000	16,288,000	5,878,000	'
Product royalty revenue	13,595,000	13,890,000	37,271,000	36,521,000	'
Product sales revenue	170,000	'	277,000	'	'
Co-promotion revenue	'	730,000	61,000	3,253,000	'
Contract and collaboration revenue	141,000	141,000	424,000	424,000	'
Total revenues	15,933,000	15,426,000	54,321,000	46,076,000	'
Cost of goods sold	3,389,000	'	3,465,000	'	'
Gross profit	12,544,000	15,426,000	50,856,000	46,076,000	'
Research and development expenses	2,467,000	2,239,000	6,446,000	6,250,000	'
Depreciation and amortization	309,000	122,000	543,000	366,000	'
Other operating expenses	8,893,000	9,677,000	27,368,000	32,475,000	'
Income (loss) from operations	875,000	3,388,000	16,499,000	6,985,000	'
Interest income	18,000	65,000	54,000	105,000	'
Other non-operating expense, net	6,000	34,000	-9,000	67,000	'
Income (loss) before income taxes	899,000	3,487,000	16,544,000	7,157,000	'
Capital expenditures	9,000	41,000	40,000	293,000	'
Property and equipment, net	975,000	'	975,000	'	1,276,000
Identifiable assets, net of intercompany loans	'	'	'	'	'
Identifiable assets, net of intercompany loans and investments	97,915,000	'	97,915,000	'	87,731,000
Europe [Member]	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Research and development revenue	'	72,000	'	74,000	'
Product sales revenue	17,000	'	37,000	'	'
Contract and collaboration revenue	12,000	-15,000	34,000	-30,000	'
Total revenues	29,000	57,000	71,000	44,000	'
Cost of goods sold	4,000	'	12,000	'	'
Gross profit	25,000	57,000	59,000	44,000	'
Research and development expenses	1,088,000	2,543,000	4,307,000	5,405,000	'
Depreciation and amortization	47,000	242,000	548,000	709,000	'
Other operating expenses	1,646,000	1,161,000	3,374,000	2,576,000	'
Income (loss) from operations	-2,756,000	-3,889,000	-8,170,000	-8,646,000	'
Interest income	2,000	3,000	8,000	12,000	'
Interest expense	-417,000	-556,000	-1,326,000	-1,656,000	'
Other non-operating expense, net	95,000	165,000	-169,000	82,000	'
Income (loss) before income taxes	-3,076,000	-4,277,000	-9,657,000	-10,208,000	'
Capital expenditures	4,000	'	110,000	3,445,000	'
Property and equipment, net	121,000	'	121,000	'	36,000
Identifiable assets, net of intercompany loans	'	'	'	'	'
Identifiable assets, net of intercompany loans and investments	13,420,000	'	13,420,000	'	25,465,000
Asia [Member]	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Research and development revenue	'	'	'	466,000	'
Product sales revenue	5,191,000	'	10,680,000	'	'
Contract and collaboration revenue	10,000	13,000	32,000	39,000	'
Total revenues	5,201,000	13,000	10,712,000	505,000	'
Cost of goods sold	2,874,000	'	5,980,000	'	'
Gross profit	2,327,000	13,000	4,732,000	505,000	'
Research and development expenses	919,000	833,000	3,775,000	2,547,000	'
Depreciation and amortization	8,000	10,000	26,000	30,000	'
Other operating expenses	563,000	322,000	2,743,000	916,000	'
Income (loss) from operations	837,000	-1,152,000	-1,812,000	-2,988,000	'
Interest income	'	'	1,000	1,000	'
Interest expense	-44,000	-40,000	-123,000	-124,000	'
Other non-operating expense, net	-150,000	-191,000	1,954,000	578,000	'
Income (loss) before income taxes	643,000	-1,383,000	20,000	-2,533,000	'
Capital expenditures	'	'	3,000	'	'
Property and equipment, net	182,000	'	182,000	'	228,000
Identifiable assets, net of intercompany loans	'	'	'	'	'
Identifiable assets, net of intercompany loans and investments	$18,385,000	'	$18,385,000	'	$14,600,000